Allosteric chromone inhibitors of phosphoinositol 3-kinase (PI3K) used to treat diseases

By designing allosteric chromone inhibitors that target the peripheral binding pocket of PI3Kα mutations, the problem of insufficient selectivity of existing PI3K inhibitors has been solved, achieving selective inhibition of mutant PI3Kα, reducing metabolic side effects, and improving the effectiveness and safety of cancer treatment.

CN117769546BActive Publication Date: 2026-11-10PETRA PHARMA CORP
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202280052177.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2021-10-07
Filing Date
2022-05-26
Publication Date
2026-11-10
Estimated Expiration
2042-05-26

AI Technical Summary

Technical Problem

Existing PI3K inhibitors have difficulty selectively inhibiting mutant PI3Kα, leading to hyperglycemia and hyperinsulinemia during systemic PI3K inhibition, which affects treatment efficacy and safety.

Method used

To develop a selective allosteric chromone inhibitor of mutant PI3Kα, by designing compounds that target the mutant peripheral binding pocket of PI3Kα to reduce the impact on wild-type PI3Kα.

Benefits of technology

It achieves selective inhibition of mutant PI3Kα, reduces the metabolic side effects of systemic PI3K inhibition, and improves the efficacy and safety of cancer treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117769546B_ABST
    Figure CN117769546B_ABST
Patent Text Reader

Abstract

This disclosure relates to compounds of formula (I) that are allosteric chromone inhibitors of phosphoinositol 3-kinase (PI3K) and can be used to treat diseases or disorders associated with PI3K regulation, or to pharmaceutically acceptable salts of formula (I) thereof, wherein R, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined herein. This disclosure also relates to methods for preparing and using compounds of formula (I) or pharmaceutically acceptable salts thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] field

[0002] This invention relates to allosteric chromone inhibitors of phosphoinositol 3-kinase (PI3K) that can be used to treat diseases or disorders associated with PI3K regulation. The invention relates to compounds and compositions that inhibit PI3K, methods (or uses) for treating diseases or disorders associated with PI3K (e.g., CLOVES syndrome (congenital lipoma overgrowth, vascular malformation, epidermal nevus, scoliosis / skeletal and spinal syndrome), PIK3CA-associated overgrowth syndrome (PROS), breast cancer, brain cancer, prostate cancer, endometrial cancer, gastric cancer, leukemia, lymphoma, sarcoma, colorectal cancer, lung cancer, ovarian cancer, skin cancer, or head and neck cancer), and methods for using PI3K inhibitors in combination with one or more other cancer therapies.

[0003] background

[0004] Cellular activity can be modulated by external signals that stimulate or inhibit intracellular events. The process of delivering stimulative or inhibitory signals into and within cells to elicit intracellular responses is called signal transduction. Over the past few decades, the cascade of signal transduction events has been elucidated and found to play a central role in a wide range of biological responses. Defects in various components of signal transduction pathways have been found to be the cause of a large number of diseases, including numerous forms of cancer, inflammatory disorders, metabolic disorders, vascular and neuronal diseases (Gaestel et al. Current Medicinal Chemistry (2007) 14:2214-2234).

[0005] Kinases represent an important class of signal transduction molecules. Kinases can generally be classified into protein kinases, lipid kinases, and certain kinases exhibiting dual specificity. Protein kinases are enzymes that phosphorylate other proteins and / or themselves (i.e., autophosphorylation). Protein kinases can generally be divided into three main categories based on their substrate utilization: tyrosine kinases that primarily phosphorylate substrates (e.g., erb2, PDGF receptor, EGF receptor, VEGF receptor, src, abl); serine / threonine kinases that primarily phosphorylate substrates (e.g., mTorC1, mTorC2, ATM, ATR, DNA-PK, Akt); and dual-specificity kinases that phosphorylate substrates on tyrosine, serine, and / or threonine residues.

[0006] Lipid kinases are enzymes that catalyze the phosphorylation of lipids within cells. These enzymes, along with the resulting phosphorylated lipids and lipid-derived biologically active organic molecules, play a role in many different physiological processes, including cell proliferation, migration, adhesion, and differentiation. A specific group of lipid kinases includes membrane lipid kinases, which are kinases that catalyze the phosphorylation of lipids contained in or associated with the cell membrane. Examples of such enzymes include phosphoinositol kinases (such as PI3-kinase and PI4-kinase), diacylglycerol kinases, and sphingosine kinases.

[0007] The phosphoinositol 3-kinase (PI3K) signaling pathway is one of the most frequently mutated systems in human cancer. PI3K signaling is involved in many other disease states, including allergic contact dermatitis, rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, chronic obstructive pulmonary disease, psoriasis, multiple sclerosis, asthma, disorders associated with diabetic complications, and inflammatory complications of the cardiovascular system such as acute coronary syndrome.

[0008] PI3Ks are members of a unique and conserved family of intracellular lipid kinases that phosphorylate the 3'-OH group on phosphatidylinositol or phosphoinositol. The PI3K family comprises 15 kinases with different substrate specificities, expression profiles, and regulatory modes (Katso et al., Annu Rev Cell Dev Biol. 2001; 17:615-75). Class I PI3Ks (p110α, p110β, p110δ, and p110γ) are typically activated by tyrosine kinases or G-protein-coupled receptors to generate PIP3, which binds to downstream effectors such as those in the Akt / PDK1 pathway, mTOR, Tec family kinases, and Rho family GTPases. Class II and III PI3Ks play a crucial role in intracellular transport through the synthesis of PI(3)P and PI(3,4)P2.

[0009] PI3K isoforms have been involved in various human cancers and disorders. Mutations in genes encoding PI3K isoforms, or mutations leading to the upregulation of PI3K isoforms, are believed to occur in many human cancers. Mutations in genes encoding PI3K is typically point mutations clustered in several hotspots within the helix and kinase domain. Due to the high mutation rate of PI3K, targeting this pathway could offer valuable therapeutic opportunities.

[0010] Genetic alterations in PI3K signaling are thought to be involved in a range of cancers, including endometrial cancer, breast cancer, esophageal squamous cell carcinoma, cervical squamous cell carcinoma, cervical adenocarcinoma, colorectal adenocarcinoma, bladder urothelial carcinoma, glioblastoma, ovarian cancer, non-small cell lung cancer, esophageal and gastric cancer, nerve sheath tumors, head and neck squamous cell carcinoma, melanoma, esophageal and gastric adenocarcinoma, soft tissue sarcoma, prostate cancer, fibrolamellar carcinoma, hepatocellular carcinoma, diffuse glioma, colorectal cancer, pancreatic cancer, bile duct cancer, B-cell lymphoma, mesothelioma, adrenocortical carcinoma, non-clear cell renal carcinoma, clear cell renal carcinoma, germ cell carcinoma, thymic tumor, pheochromocytoma, various neuroepithelial tumors, thyroid cancer, leukemia, and encapsulated glioma (Goncalves MD, Hopkins BD, Cantley LC. Phosphatidylinositol 3-Kinase, Growth Disorders, and Cancer. N Engl J). Med. 2018 Nov 22;379(21):2052-2062).

[0011] The α (alpha) isoform of PI3K has been involved in various human cancers, for example. Angiogenesis has been shown to selectively require the α isoform of PI3K to control endothelial cell migration (Graupera et al., Nature 2008; 453; 662-6). Mutations in genes encoding PI3Kα, or mutations leading to PI3Kα upregulation, are thought to occur in many human cancers, such as lung cancer, gastric cancer, endometrial cancer, ovarian cancer, bladder cancer, breast cancer, colon cancer, brain cancer, prostate cancer, and skin cancer. Mutations in genes encoding PI3Kα are point mutations clustered in several hotspots in the helical and kinase domains, such as E542K, E545K, and H1047R. Many of these mutations have been shown to be oncogenic gain-of-function mutations. Due to the high mutation rate of PI3Kα, targeting this pathway could provide valuable therapeutic opportunities. While other PI3K isoforms such as PI3Kδ or PI3Kγ are primarily expressed in hematopoietic cells, PI3Kα and PI3Kβ are constitutively expressed.

[0012] Mutated PI3Kα has been involved in brain metastases in HR+ / HER2- metastatic breast cancer. The development of brain-penetrating PI3Kα inhibitors may provide improved therapeutic benefits compared to current PI3Kα inhibitors. (Fitzgerald et al., Association between PIK3CA mutation status and development of brain metastases in HR+ / HER2-metastatic breast cancer. Ann Oncol 30:v110, 2019(Supplement 5)).

[0013] Because of PI3Kα's central role in regulating glucose homeostasis, PI3K inhibition in patients often leads to hyperglycemia and / or hyperinsulinemia (Busaidy NL et al., Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol 2012; 30:2919-28). High levels of circulating insulin may have mitogenic and / or anti-apoptotic effects on cancer cells, thereby counteracting the antiproliferative effects of PI3K inhibitors (Blouin M-J et al., Abstract 4615: the hyperinsulinemia caused by PI3K inhibitors attenuates their antineoplastic efficacy, but can be minimized by co-administration of metformin. Cancer Res 2013; 73:4615).

[0014] In the case of cancers with mutated PI3Kα, one approach to overcome the problem of insulin and / or glucose compensation following systemic PI3Kα inhibition is to develop inhibitors that are more selective for mutant PI3Kα than wild-type PI3Kα. This will create an increased window for drug delivery to selectively inhibit pathological signaling of mutant PI3Kα in cancer cells without affecting wild-type PI3Kα in host tissues that control systemic metabolism (Okkenhaug K, Graupera M, Vanhaesebroeck B. Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy. Cancer Discov. 2016 Oct; 6(10):1090-1105), thereby limiting toxicity and allowing for higher doses and more complete inhibition of the drug target (Ariella B. Hanker et al., Challenges for the clinical development of PI3K inhibitors: Strategies to improve their impact in solid tumors. Cancer Discov. 2019 Apr; 9(4):482-491).

[0015] Currently, PI3Kα inhibitors are nearly equivalent to wild-type and mutant PI3Kα. Because PI3Kα mutations are located far from the active site, selective inhibitors for mutants have been elusive. Therefore, inhibitors targeting the second peripheral binding pocket near known mutations (e.g., H1047R) may offer a pathway for selectively inhibiting PI3Kα. Thus, targeting the mutant peripheral binding pocket of PI3Kα provides a valuable therapeutic target for drug development.

[0016] Therefore, kinases, such as lipid kinases like PI3K, are major targets for drug development. This invention provides a novel class of kinase inhibitors.

[0017] Overview

[0018] In one aspect, the present invention relates to compounds of formula (I):

[0019]

[0020] Or its pharmaceutically acceptable salt, wherein:

[0021] R is -H or C1-C3 alkyl;

[0022] R1 is a group in the following formula:

[0023]

[0024]

[0025] R2 is optionally substituted with a bicyclic compound selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one, or 2,3-dihydro-[1,4]dioxacyclohexen[2,3-b]pyridine, or optionally substituted with a bicyclic compound containing 1, 2, 3, 4, or 5 independently substituted compounds. A bicyclic heteroaryl group consisting of 8 to 10 ring atoms selected from N, O, or S; wherein the optionally substituted bicyclic group is optionally substituted by 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl group is optionally substituted by 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -SO2R 10 -C(O)OC1-C3 alkyl, -CONR 10 R 10 -NR 10 R 10 -NR 10 CO2R 10 -OH, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, optionally substituted 1,3-benzodioxane, optionally substituted 2,3-dihydro-1,4-benzodioxane, or optionally substituted heteroaryl selected from pyridine, pyrimidine, pyridazine, pyrazine, pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl is each optionally replaced by -CN, -OH, oxetyl, C1-C3 alkoxy, -CONR 10 R 10 Or phenyl substitution; the optionally substituted C3-C5 cycloalkyl, phenyl, 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, heterocyclic or heteroaryl group is each optionally substituted by 1 to 3 substituents, each substituent being independently selected from halogens, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -SO2R 10-NR 10 R 10 -OH or -CN;

[0026] R3 is -H, halogen, -CN, -N(H)(C1-C3 alkyl), -N(C1-C3 alkyl)2, -N(H)(CH2CH2CO2H), -C(O)C1-C3 alkyl, C1-C6 alkylC1-C6 haloalkyl, C1-C6 hydroxyalkyl, C3-C5 cycloalkyl, optionally substituted heterocycles containing 3 to 5 ring atoms of 1, 2 or 3 ring heteroatoms independently selected from N, O or S, or optionally substituted heteroaryl groups containing 5 or 6 ring atoms of 1, 2 or 3 ring heteroatoms independently selected from N, O or S; wherein each optionally substituted heterocycle or heteroaryl group is optionally substituted by 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl or C1-C3 haloalkyl;

[0027] Each of R4, R5 and R6 is independently -H, halogen, C1-C6 alkyl or C1-C6 haloalkyl;

[0028] R7 is -CN, C1-C6 alkyl, or C1-C6 haloalkyl;

[0029] R8 is -H or C1-C6 alkyl;

[0030] Each R9 is independently -H, halogen, -CN, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C3-C5 cycloalkyl; and

[0031] Each R 10 It is independently -H or C1-C3 alkyl.

[0032] In another aspect, the present invention provides a pharmaceutical composition comprising a compound of formula (I), (II) or (III) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.

[0033] In another aspect, the present invention provides a method for modulating PI3K (e.g., PI3Kα) activity (e.g., in vitro or in vivo), the method comprising contacting cells with a therapeutically effective amount of a compound of formula (I), (II) or (III) or a pharmaceutically acceptable salt thereof.

[0034] In some respects, the present invention provides a method for treating or preventing a disease or disorder disclosed herein in a subject in need of such treatment, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I), (II), or (III) or a pharmaceutically acceptable salt thereof.

[0035] In some respects, the present invention provides a method for treating or preventing a disease or disorder disclosed herein in a subject in need of such treatment, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition of a compound of formula (I), (II), or (III) or a pharmaceutically acceptable salt thereof.

[0036] In some respects, the present invention provides a method for treating a disease or disorder disclosed herein in a subject in need of such treatment, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I), (II), or (III) or a pharmaceutically acceptable salt thereof.

[0037] In some aspects, the present invention provides a method for treating a disease or disorder disclosed herein in a subject in need of such treatment, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition of a compound of formula (I), (II), or (III) or a pharmaceutically acceptable salt thereof.

[0038] In another aspect, the present invention provides compounds of formula (I), (II) or (III) or pharmaceutically acceptable salts thereof for therapeutic purposes.

[0039] In another aspect, the present invention provides compounds of formula (I), (II) or (III) or pharmaceutically acceptable salts thereof for modulating PI3K (e.g., PI3Kα) activity (e.g., in vitro or in vivo).

[0040] In another aspect, the present invention provides compounds of formula (I), (II) or (III) or pharmaceutically acceptable salts thereof for selectively inhibiting mutant PI3Kα relative to wild-type PI3Kα.

[0041] In another aspect, the present invention provides compounds of formula (I), (II) or (III) or pharmaceutically acceptable salts thereof for the treatment or prevention of the diseases or disorders disclosed herein.

[0042] In another aspect, the present invention provides compounds of formula (I), (II) or (III) or pharmaceutically acceptable salts thereof for the treatment of the diseases or disorders disclosed herein.

[0043] In another aspect, the present invention provides the use of compounds of formula (I), (II) or (III) or pharmaceutically acceptable salts thereof in the preparation of medicaments for modulating PI3K (e.g., PI3Kα) activity (e.g., in vitro or in vivo).

[0044] In another aspect, the present invention provides the use of compounds of formula (I), (II) or (III) or pharmaceutically acceptable salts thereof in the preparation of medicaments for the treatment or prevention of diseases or disorders disclosed herein.

[0045] In another aspect, the present invention provides the use of compounds of formula (I), (II) or (III) or pharmaceutically acceptable salts thereof in the preparation of medicaments for treating the diseases or disorders disclosed herein.

[0046] In another aspect, the present invention provides a method for preparing a compound of formula (I), (II) or (III) or a pharmaceutically acceptable salt thereof.

[0047] In another aspect, the present invention provides a method for preparing a compound, the method comprising one or more steps described herein.

[0048] In another aspect, the present invention provides compounds that are obtainable or obtained by the methods for preparing compounds described herein (e.g., methods including one or more steps described in the scheme).

[0049] In another aspect, the present invention provides intermediates as described herein (e.g., the intermediates are selected from those described in the examples) suitable for use in the methods for preparing compounds described herein.

[0050] Other features and advantages of the invention will become apparent from the following detailed description and claims.

[0051] Detailed description

[0052] This invention provides a method (or use in treating, preventing, or improving diseases or disorders in which PI3K plays a role) by administering a therapeutically effective amount of the PI3K inhibitor of this invention to a patient in need. The method (or use) of this invention can be used to treat a variety of PI3K-dependent diseases and disorders.

[0053] In some implementations, the disease or disorder is cancer (e.g., breast cancer, brain cancer, prostate cancer, endometrial cancer, stomach cancer, leukemia, lymphoma, sarcoma, colorectal cancer, lung cancer, ovarian cancer, skin cancer, or head and neck cancer). In some implementations, the PI3K-related diseases or disorders include, but are not limited to, CLOVES syndrome (congenital lipoma overgrowth, vascular malformation, epidermal nevus, scoliosis / skeletal and spinal syndrome), PIK3CA-associated overgrowth syndrome (PROS), endometrial cancer, breast cancer, esophageal squamous cell carcinoma, cervical squamous cell carcinoma, cervical adenocarcinoma, colorectal adenocarcinoma, bladder urothelial carcinoma, glioblastoma, ovarian cancer, non-small cell lung cancer, esophageal and gastric cancer, nerve sheath tumors, head and neck squamous cell carcinoma, melanoma, esophageal and gastric adenocarcinoma, soft tissue sarcoma, prostate cancer, fibrolamellar carcinoma, hepatocellular carcinoma, diffuse glioma, colorectal cancer, pancreatic cancer, bile duct cancer, B-cell lymphoma, mesothelioma, adrenocortical carcinoma, non-clear cell renal carcinoma, clear cell renal carcinoma, germ cell carcinoma, thymic tumor, pheochromocytoma, miscellaneous neuroepithelial tumors, thyroid cancer, leukemia, and encapsulated glioma.

[0054] The details of the invention are set forth in the following appended description. Although similar or equivalent methods and materials to those described herein may be used in the practice or experimentation of this disclosure, exemplary methods and materials are described now. Other features, objects, and advantages of the invention will be apparent from the specification and claims. In the specification and appended claims, the singular form also includes the plural form unless the context clearly indicates otherwise. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. All patents and publications referenced in this specification are incorporated herein by reference in their entirety.

[0055] definition

[0056] The article “a species” refers to one or more species among the grammatical objects of the article (i.e., at least one species). For example, “a species element” refers to one or more species elements.

[0057] The term “and / or” means “and” or “or”, unless otherwise specified.

[0058] The term “administration” means the direct administration of a publicly disclosed compound, or a pharmaceutically acceptable salt of a publicly disclosed compound, or a combination thereof, to a subject.

[0059] The term "alkenyl" refers to a straight-chain or branched unsaturated hydrocarbon containing 2 to 12 carbon atoms. An alkenyl group contains at least one double bond in its chain. The double bond in an alkenyl group can be non-conjugated or conjugated with another unsaturated group. Examples of alkenyl groups include vinyl, propenyl, n-butenyl, isobutenyl, pentenyl, or hexenyl.

[0060] The term "alkoxy" refers to a straight-chain or branched saturated hydrocarbon containing 1 to 12 carbon atoms, ending in an "O" at the end of the chain; that is, -O (alkyl). Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, tert-butoxy, or pentoxy.

[0061] The term "alkyl" refers to a straight-chain or branched saturated hydrocarbon containing 1 to 12 carbon atoms, preferably 1 to 6 carbon atoms. Examples of (C1-C6) alkyl groups include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, neopentyl, and isohexyl.

[0062] The term "alkynyl" refers to a straight-chain or branched unsaturated hydrocarbon containing 2 to 12 carbon atoms. An alkynyl group contains at least one triple bond in its chain. Examples of alkynyl groups include ethynyl, propynyl, n-butynyl, isobutynyl, pentyynyl, or hexynyl.

[0063] The term "aromatic" refers to a planar ring with 4n+2 electrons in a conjugated system. As used herein, "conjugated system" refers to a system with connected p-orbitals containing delocalized electrons, and this system may include lone pairs.

[0064] Unless otherwise specifically defined, the term "aryl" refers to a cyclic aromatic group having 1 to 3 aromatic rings, including monocyclic or bicyclic groups such as phenyl, biphenyl, or naphthyl. In the case of two aromatic rings (bicyclic, etc.), the aromatic rings of the aryl group may be joined at a single point (e.g., biphenyl) or fused (e.g., naphthyl). Furthermore, when containing two fused rings, the aryl group as defined herein may have one or more saturated or partially unsaturated rings fused to fully unsaturated aromatic rings. Exemplary ring systems of these aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl, anthracene, phenatenyl, phenanthyl, indanyl, indenyl, tetrahydronaphthyl, and tetrahydrobenzoxenyl.

[0065] The term “carrier” encompasses carriers, excipients, and diluents, and refers to materials, compositions, or media that participate in carrying or transporting a pharmaceutical agent from one organ or part of a subject’s body to another organ or part of the body, such as liquid or solid fillers, diluents, excipients, solvents, or encapsulating materials.

[0066] The term "cyano" refers to a substituent that has a carbon atom attached to a nitrogen atom via a triple bond, i.e., C≡N.

[0067] The term "cycloalkyl" refers to a monocyclic or polycyclic saturated carbon ring containing 3 to 18 carbon atoms, preferably 3 to 10 carbon atoms. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbornyl, norbornyl, bicyclo[2.2.2]octyl, and bicyclo[2.2.2]octenyl.

[0068] Unless otherwise specified, the term “disorder” refers to the term disease, symptom or illness and is used interchangeably with the term disease, symptom or illness.

[0069] The term "haloalkoxy" refers to an alkoxy group as defined herein that has been substituted with one or more halogens. Examples of haloalkoxy groups include, but are not limited to, trifluoromethoxy, difluoromethoxy, pentafluoroethoxy, and trichloromethoxy.

[0070] The term "haloalkyl" refers to an alkyl group as defined herein that has been substituted with one or more halogens. Examples of haloalkyl groups include, but are not limited to, trifluoromethyl, difluoromethyl, pentafluoroethyl, and trichloromethyl.

[0071] The term "halogen" or "halogenated" refers to fluorine, chlorine, bromine, or iodine.

[0072] Unless otherwise specifically defined, the term "heteroaryl" refers to a monovalent monocyclic or polycyclic aromatic group with 5-24 ring atoms, preferably 5-10 ring atoms, containing one or more cyclic heteroatoms selected from N, O, S, P, or B, preferably 1, 2, 3, or 4 cyclic heteroatoms selected from N, O, or S, with the remaining ring atoms being C. Polycyclic aromatic groups comprise two or more fused rings and may further comprise two or more spiro-fused rings, for example, bicyclic, tricyclic, tetracyclic, etc. Unless otherwise specifically defined, "fused" means two rings sharing two ring atoms. Unless otherwise specifically defined, "spiro-fused" means two rings sharing one ring atom. As defined herein, a heteroaryl also means a bicyclic heteroaryl group, wherein the heteroatom is selected from N, O, S, P, or B, preferably N, O, or S. As defined herein, a heteroaryl also means a tricyclic heteroaryl group, containing one or more cyclic heteroatoms selected from N, O, S, P, or B, preferably N, O, or S. As defined herein, heteroaryl also refers to a tetracyclic heteroaryl group containing one or more cyclic heteroatoms selected from N, O, S, P or B, preferably N, O or S.Examples of heteroaromatic groups include, but are not limited to, furanyl, thiophene, pyrrolyl, pyridyl, pyrazolyl, pyrimidinyl, imidazoleyl, isoxazolyl, oxazolyl, oxadiazolyl, pyrazinyl, indoleyl, thiophene-2-yl, quinolinyl, benzopyranyl, isothiazolyl, thiazolyl, thiadiazole, indazole, benzimidazolyl, thieno[3,2-b]thiophene, triazolyl, triazinyl, imidazo[1,2-b]pyrazolyl, furan[2,3-c]pyridyl, imidazo[1,2-a]pyridyl, indazoleyl, pyrrolo[2,3-c]pyridyl, pyrrolo[3,2-c]pyridyl, pyrazolo[3,4-c]pyridyl, thieno[3,2-c]pyridyl, and thieno[3,2-c]pyridyl. Pyridyl, thieno[2,3-c]pyridyl, thieno[2,3-b]pyridyl, benzothiazolyl, indololinyl, indololinone, dihydrobenzothiaphenyl, dihydrobenzofuranyl, benzofuranyl, chromanyl, thiochromanyl, tetrahydroquinolinyl, dihydrobenzothiazinyl, quinolinyl, isoquinolinyl, 1,6-naphthidyl, benzo[de]isoquinolinyl, pyrido[4,3-b][1,6]naphthidyl, thieno[2,3-b]pyrazinyl, quinazolinyl, tetrazo[1,5-a]pyridyl, [1,2,4]triazo[4,3-a]pyridyl, isoindolyl, pyrrolo[2,3-b]pyridyl, pyrrolo[3,4]pyridyl -b]pyridyl, pyrrolo[3,2-b]pyridyl, imidazo[5,4-b]pyridyl, pyrrolo[1,2-a]pyrimidinyl, tetrahydropyrrolo[1,2-a]pyrimidinyl, 3,4-dihydro-2H-1-pyrrolo[2,1-b]pyrimidinyl, dibenzo[b,d]thiophene, pyridin-2-one, furano[3,2-c]pyridyl, furano[2,3-c]pyridyl, 1H-pyrido[3,4-b][1,4]thiazinyl, benzoxazolyl, benzoisoxazolyl, furano[2,3-b]pyridyl, benzothiophene, 1,5-naphthidyl, furano[3,2-b]pyridine, [1,2,4]triazol[ [1,5-a]pyridyl, benzo[1,2,3]triazolyl, imidazo[1,2-a]pyrimidinyl, [1,2,4]triazol[4,3-b]pyridazinyl, benzo[c][1,2,5]thiadiazolyl, benzo[c][1,2,5]oxadiazole, 1,3-dihydro-2H-benzo[d]imidazol-2-one, 3,4-dihydro-2H-pyrazolo[1,5-b][1,2]oxazinyl, 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridyl, thiazo[5,4-d]thiazolyl, imidazo[2,1-b][1,3,4]thiadiazolyl, thieno[2,3-b]pyrroleyl, and 3H-indolyl. Furthermore, when containing two or more fused rings, the heteroaryl group defined herein may have one or more saturated or partially unsaturated rings fused with one or more fully unsaturated aromatic rings.In heteroaryl ring systems containing more than two fused rings, a saturated or partially unsaturated ring may be further fused with a saturated or partially unsaturated ring as described herein. Furthermore, when three or more fused rings are present, a heteroaryl group as defined herein may have one or more spiro-fused saturated or partially unsaturated rings. Any saturated or partially unsaturated ring described herein may optionally be substituted with one or more oxo groups. Exemplary ring systems of these heteroaryl groups include, for example, indololinyl, indololinone, dihydrobenzothiophene, dihydrobenzofuran, chromanyl, thiochromanyl, tetrahydroquinolinyl, dihydrobenzothiazine, 3,4-dihydro-1H-isoquinolinyl, 2,3-dihydrobenzofuranyl, benzofuranone, hydroxyindolyl, indolyl, 1,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one, 7,8-dihydro-6H-pyrido[3,2-b]pyrrolazinyl, 8H-pyrido[3,2-b]pyrrolazinyl, 1,5,6,7-tetrahydrocyclopentadien[b]pyrazolo[4,3-e]pyridinyl, 7,8-dihydro-6H-pyrido[3,2]pyridinyl, and 7,2 -b]pyrrolizinyl, pyrazolo[1,5-a]pyrimidin-7(4H)-ketol, 3,4-dihydropyrazolo[1,2-a]indole-1(2H)-ketol, benzo[c][1,2]oxaborol-1(3H)-olyl, 6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin-9-ketol and 6a',7'-dihydro-6'H,9'H-spiro[cyclopropane-1,8'-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin]-9'-ketol. Other exemplary bicyclic heteroaryl groups include, but are not limited to, indole, benzothiophene, benzofuran, isoindole, benzo[c]thiophene, isobenzofuran, indazole, benzimidazole, benzoxazole, benzothiazole, benzoisoxazole, benzoisothiazole, pyrrolopyridine, furanopyridine, thienopyridine, pyrazolopyridine, isoxazolpyridine, isothiazolpyridine, imidazopyridine, oxazolpyridine, thiazopyridine, pyrrolopyrazine, pyrrolopyrimidine, pyrrolopyrazine, furanopyrazine, furanopyrimidine, furanopyrazine, thienopyrazine, thienopyrimidine, thienopyrazine, pyrazolopyrazine, pyrazolopyrazine Pyrimidine, pyrazolopyrazine, pyrazolopyrazine, isoxazolidine, isoxazolidine, isoxazolidine, isothiazolidine, isothiazolidine, isothiazolidine, imidazopyrazine, imidazopyrimidine, imidazopyrazine, oxazolidine, oxazolidine, oxazolidine, thiazopyrazine, thiazopyrimidine, thiazopyrazine, quinazoline, quinoxaline, cinnazoline, phthalazine, pyridopyrazine, pyridopyrimidine, pyridopyrazine, pyrazopyrazine, pyrimidine, pyrazopyrazine, pyrimidine, pyridopyrazine, pyrimidine, pteridine, pyrazopyrazine, pyridopyrazine, pyrazopyrazine, pyrazopyrazine, pyrimidine, pyrazopyrazine, pyrazopyrazine, pyrazopyrazine and pyrazopyrazine.

[0073] The terms “heterocyclic group,” “heterocyclic” or “heterocyclic alkyl” refer to a monocyclic or polycyclic ring containing 3 to 24 atoms, preferably 3 to 10 atoms, comprising carbon and one or more heteroatoms selected from N, O, S, P or B, preferably 1, 2, 3 or 4 heteroatoms selected from N, O and S, and wherein said ring is not aromatic. Examples of heterocyclic groups include, but are not limited to, oxoheterobutyl, azaheterobutyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, oxazolinyl, oxazolinyl, thiazolinyl, thiazolinyl, pyranyl, thiaranyl, tetrahydropyranyl, dioxalinyl, piperidinyl, morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S-dioxide, piperazine, azaheptatrienyl, oxoheptatrienyl, diazaheptatrienyl, hyoscyamine, oxazolidinone, and homotropanyl.

[0074] The term "hydroxyalkyl" refers to an alkyl group that has been substituted with a hydroxyl group, as defined herein.

[0075] The term "isomer" refers to compounds with the same molecular formula but different atomic bonding properties or sequences, or different spatial arrangements of their atoms. Isomers with different spatial arrangements of atoms are called "stereoisomers." Stereoisomers that are not mirror images of each other are called "diastereomers," and stereoisomers that are non-overlapping mirror images of each other are called "enantiomers." A pair of enantiomers is possible when a compound has an asymmetric center (e.g., it is bonded to four different groups). Enantiomers can be characterized by the absolute configuration of their asymmetric center and described by the R- and S-sequencing rules of Cahn and Prelog, or by the way the molecule rotates the plane of polarized light and is specified as dextrorotatory or levorotatory (i.e., (+)-isomers or (-)-isomers, respectively). Chiral compounds can exist as single enantiomers or as mixtures thereof. A mixture containing equal proportions of enantiomers is called a "racemic mixture."

[0076] The term "regulation" refers to the biological activity of compounds or substrates that inhibit and / or activate PI3K.

[0077] The term "patient" or "subject" refers to a mammal, such as a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or a non-human primate, such as a monkey, chimpanzee, baboon, or rhesus monkey. Preferably, the mammal is a human.

[0078] When used in connection with a compound, the term "therapeutic effective amount" refers to the amount or dose of such a compound that, when administered to a patient in a single or multiple doses, provides the desired effect in a patient undergoing diagnosis or treatment. Those skilled in the art can determine the effective amount by using known techniques and by observing results obtained in similar situations. In determining the effective amount for a patient, the attending physician considers many factors, including, but not limited to: the patient's species; their body type, age, and general health condition; the specific disease or disorder involved; the extent or severity of the disease or disorder; the individual patient's response; the specific compound administered; the mode of administration; the bioavailability characteristics of the administered product; the chosen dosing regimen; the use of concomitant medications; and other relevant circumstances.

[0079] The term "treatment" for subjects includes suppressing, slowing, stopping, or reversing the progression or severity of existing symptoms or disorders.

[0080] The compounds of the present invention

[0081] In one aspect, the present invention provides compounds of formula (I) or pharmaceutically acceptable salts thereof:

[0082]

[0083] R, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined in the overview with respect to equation (I).

[0084] In another respect, compounds of formula (I) (where R8 is H) have a formula (II) or a pharmaceutically acceptable salt thereof:

[0085]

[0086] R, R1, R2, R3, R4, R5, R6 and R7 are as defined in the overview with respect to equation (I).

[0087] In compounds of formula (I) or pharmaceutically acceptable salts thereof,

[0088] R is -H or C1-C3 alkyl;

[0089] R1 is a group in the following formula:

[0090]

[0091] R2 is optionally substituted with a bicyclic compound selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one, or 2,3-dihydro-[1,4]dioxacyclohexen[2,3-b]pyridine, or optionally substituted with a bicyclic compound containing 1, 2, 3, 4, or 5 independently substituted compounds. A bicyclic heteroaryl group consisting of 8 to 10 ring atoms selected from N, O, or S; wherein the optionally substituted bicyclic group is optionally substituted by 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl group is optionally substituted by 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -SO2R 10 -CONR 10 R 10 -NR 10 R 10 -NR 10 CO2R 10 Optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 ynyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, optionally substituted 1,3-benzodioxane, optionally substituted 2,3-dihydro-1,4-benzodioxane, or optionally substituted heteroaryl selected from pyridine, pyrimidine, pyridazine, pyrazine, pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein... The optionally substituted C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl groups are each optionally substituted with -CN, -OH, oxetyl, or C1-C3 alkoxy groups; the optionally substituted C3-C5 cycloalkyl, phenyl, 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, heterocyclic, or heteroaryl groups are each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens, C1-C3 alkyl groups, C1-C3 haloalkyl groups, C1-C3 alkoxy groups, C1-C3 haloalkoxy groups, and -SO2R groups. 10 -NR 10 R 10 -OH or -CN;

[0092] R3 is -H, halogen, -CN, C1-C6 alkyl, C1-C6 haloalkyl, C3-C5 cycloalkyl, a heterocycle containing 3 to 5 ring atoms of 1, 2 or 3 ring heteroatoms independently selected from N, O or S, or a heteroaryl group containing 5 ring atoms of 1, 2 or 3 ring heteroatoms independently selected from N, O or S.

[0093] Each of R4, R5 and R6 is independently -H, halogen, C1-C6 alkyl or C1-C6 haloalkyl;

[0094] R7 is -CN, C1-C6 alkyl, or C1-C6 haloalkyl;

[0095] R8 is -H or C1-C6 alkyl;

[0096] Each R9 is independently -H, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C3-C5 cycloalkyl; and

[0097] Each R 10 It is independently -H or C1-C3 alkyl.

[0098] In compounds of formula (I) or pharmaceutically acceptable salts thereof,

[0099] R is -H or C1-C3 alkyl;

[0100] R1 is a group in the following formula:

[0101]

[0102]

[0103] R2 is a bicyclic compound optionally substituted from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindoline-1-one, indoline-2-one, or benzo[d]oxazol-2(3H)-one, or a bicyclic heteroaryl compound optionally substituted with 8 to 10 ring atoms containing 1, 2, 3, 4, or 5 ring heteroatoms independently selected from N, O, or S; wherein the optionally substituted bicyclic compound is optionally substituted with 1 to 3 substituents, each substituent independently selected from halogens and C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl compound is optionally substituted with 1 to 3 substituents, each substituent independently selected from -CN, halogens, C1-C6 haloalkyl groups, C1-C6 alkoxy groups, C1-C6 haloalkoxy groups, -SO2R 10 -CONR 10 R 10 -NR 10 R 10 -NR 10 CO2R 10The optionally substituted C1-C6 alkyl group, the optionally substituted C3-C5 cycloalkyl group, the optionally substituted heterocyclic group selected from pyrrolidine, pyrrolidone, piperidine, or morpholine, the optionally substituted phenyl group, or the optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy group; and each of the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is optionally substituted with 1 to 3 substituents, each of which is independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN;

[0104] R3 is -H, -CN, C1-C6 alkyl, or C1-C6 haloalkyl;

[0105] Each of R4, R5 and R6 is independently -H, halogen, C1-C6 alkyl or C1-C6 haloalkyl;

[0106] R7 is -CN, C1-C6 alkyl, or C1-C6 haloalkyl;

[0107] R8 is -H or C1-C6 alkyl;

[0108] Each R9 is independently -H, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C3-C5 cycloalkyl; and

[0109] Each R 10 It is independently -H or C1-C3 alkyl.

[0110] In compounds of formula (I) or pharmaceutically acceptable salts thereof,

[0111] R is -H or C1-C3 alkyl;

[0112] R1 is a group in the following formula:

[0113]

[0114] R2 is a optionally substituted bicyclic ring selected from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, or benzo[d]oxazol-2(3H)-one, or an optionally substituted bicyclic heteroaryl ring, wherein the phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to a pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; wherein the optionally substituted bicyclic ring is optionally substituted by 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl; wherein the optionally substituted bicyclic heteroaryl ring is optionally substituted by 1 to 3 substituents, each substituent being independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -SO2R 10 -CONR 10 R 10 -NR 10 R 10 -NR 10 CO2R 10 The optionally substituted C1-C6 alkyl group, the optionally substituted C3-C5 cycloalkyl group, the optionally substituted heterocyclic group selected from pyrrolidine, pyrrolidone, piperidine, or morpholine, the optionally substituted phenyl group, or the optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy group; and each of the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is optionally substituted with 1 to 3 substituents, each of which is independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN;

[0115] R3 is -H, -CN, C1-C6 alkyl, or C1-C6 haloalkyl;

[0116] Each of R4, R5 and R6 is independently -H, halogen, C1-C6 alkyl or C1-C6 haloalkyl;

[0117] R7 is -CN, C1-C6 alkyl, or C1-C6 haloalkyl;

[0118] R8 is -H or C1-C6 alkyl;

[0119] Each R9 is independently -H, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C3-C5 cycloalkyl; and

[0120] Each R 10It is independently -H or C1-C3 alkyl.

[0121] In compounds of formula (I) or (II) or their pharmaceutically acceptable salts, R2 is optionally substituted from a bicyclic compound selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one or 2,3-dihydro-[1,4]dioxacyclohexeno[2,3-b]pyridine, or optionally substituted from a bicyclic compound containing... A bicyclic heteroaryl group consisting of 1, 2, 3, 4, or 5 cyclic heteroatoms independently selected from N, O, or S, comprising 8 to 10 cyclic atoms; wherein the optionally substituted bicyclic group is optionally substituted by 1 to 3 substituents, each substituent independently selected from halogens and C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl group is optionally substituted by 1 to 3 substituents, each substituent independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -SO2R. 10 -CONR 10 R 10 -NR 10 R 10 -NR 10 CO2R 10 Optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 ynyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, optionally substituted 1,3-benzodioxane, optionally substituted 2,3-dihydro-1,4-benzodioxane, or optionally substituted heteroaryl selected from pyridine, pyrimidine, pyridazine, pyrazine, pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein... The optionally substituted C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl groups are each optionally substituted with -CN, -OH, oxetyl, or C1-C3 alkoxy groups; the optionally substituted C3-C5 cycloalkyl, phenyl, 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, heterocyclic, or heteroaryl groups are each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens, C1-C3 alkyl groups, C1-C3 haloalkyl groups, C1-C3 alkoxy groups, C1-C3 haloalkoxy groups, and -SO2R groups. 10 -NR 10 R 10 -OH or -CN.

[0122] In compounds of formula (I) or (II) or their pharmaceutically acceptable salts, R2 is a bicyclic compound optionally substituted from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, indololin-2-one, or benzo[d]oxazol-2(3H)-one, or a bicyclic heteroaryl compound optionally substituted with 8 to 10 ring atoms containing 1, 2, 3, 4, or 5 ring heteroatoms independently selected from N, O, or S; wherein the optionally substituted bicyclic compound is optionally substituted with 1 to 3 substituents, each substituent independently selected from halogens and C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl compound is optionally substituted with 1 to 3 substituents, each substituent independently selected from -CN, halogens, C1-C6 haloalkyl groups, C1-C6 alkoxy groups, C1-C6 haloalkoxy groups, -SO2R 10 -CONR 10 R 10 -NR 10 R 10 -NR 10 CO2R 10 The optionally substituted C1-C6 alkyl group, the optionally substituted C3-C5 cycloalkyl group, the optionally substituted heterocyclic group selected from pyrrolidine, pyrrolidone, piperidine, or morpholine, the optionally substituted phenyl group, or the optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy group; and each of the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is optionally substituted with 1 to 3 substituents, each of which is independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0123] In compounds of formula (I) or (II) or their pharmaceutically acceptable salts, R2 is an optionally substituted bicyclic heteroaryl group, and said optionally substituted bicyclic heteroaryl group is a phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring fused with a pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; wherein said optionally substituted bicyclic heteroaryl group is optionally substituted by 1 to 3 substituents, each substituent being independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -SO2R 10 -C(O)OC1-C3 alkyl, -CONR 10 R 10 -NR 10 R 10-NR 10 CO2R 10 -OH, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, optionally substituted 1,3-benzodioxane, optionally substituted 2,3-dihydro-1,4-benzodioxane, or optionally substituted heteroaryl selected from pyridine, pyrimidine, pyridazine, pyrazine, pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl is each optionally replaced by -CN, -OH, oxetyl, C1-C3 alkoxy, -CONR 10 R 10 Or phenyl substitution; the optionally substituted C3-C5 cycloalkyl, phenyl, 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, heterocyclic or heteroaryl group is each optionally substituted by 1 to 3 substituents, each substituent being independently selected from halogens, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -SO2R 10 -NR 10 R 10 -OH or -CN

[0124] In compounds of formula (I) or (II) or their pharmaceutically acceptable salts, R2 is an optionally substituted bicyclic heteroaryl group, and said optionally substituted bicyclic heteroaryl group is a phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring fused with a pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; wherein said optionally substituted bicyclic heteroaryl group is optionally substituted by 1 to 3 substituents, each substituent being independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -SO2R 10 -CONR 10 R 10 -NR 10 R 10 -NR 10 CO2R 10Optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 ynyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, optionally substituted 1,3-benzodioxane, optionally substituted 2,3-dihydro-1,4-benzodioxane, or optionally substituted heteroaryl selected from pyridine, pyrimidine, pyridazine, pyrazine, pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein... The optionally substituted C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl groups are each optionally substituted with -CN, -OH, oxetyl, or C1-C3 alkoxy groups; the optionally substituted C3-C5 cycloalkyl, phenyl, 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, heterocyclic, or heteroaryl groups are each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens, C1-C3 alkyl groups, C1-C3 haloalkyl groups, C1-C3 alkoxy groups, C1-C3 haloalkoxy groups, and -SO2R groups. 10 -NR 10 R 10 -OH or -CN; preferably, the optionally substituted bicyclic heteroaryl group is optionally substituted by 1 to 3 substituents, each substituent being independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -SO2R 10 -CONR 10 R 10 -NR 10 R 10 -NR 10 CO2R 10 The optionally substituted C1-C6 alkyl group, the optionally substituted C3-C5 cycloalkyl group, the optionally substituted heterocyclic group selected from pyrrolidine, pyrrolidone, piperidine, or morpholine, the optionally substituted phenyl group, or the optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy group; and each of the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is optionally substituted with 1 to 3 substituents, each of which is independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0125] In compounds of formula (I) or (II) or their pharmaceutically acceptable salts, R2 is optionally substituted bicyclic selected from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, indololin-2-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted bicyclic heteroaryl, wherein the phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to pyrrole, furan, thiophene, pyrazole, isoxazol, The ring may contain imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine; wherein the optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl groups, C1-C6 alkoxy groups, C1-C6 haloalkoxy groups, and -SO2R. 10 -CONR 10 R 10 -NR 10 R 10 -NR 10 CO2R 10 The optionally substituted C1-C6 alkyl group, the optionally substituted C3-C5 cycloalkyl group, the optionally substituted heterocyclic group selected from pyrrolidine, pyrrolidone, piperidine, or morpholine, the optionally substituted phenyl group, or the optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy group; and each of the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is optionally substituted with 1 to 3 substituents, each of which is independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0126] In compounds of formula (I) or (II) or their pharmaceutically acceptable salts, R2 is optionally substituted bicyclic selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted bicyclic heteroaryl, wherein the phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to pyrrole, furan, thiophene, pyrazole, isoxazol, or imidazole. The alternatively substituted bicyclic ring may contain oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine rings; wherein the optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -SO2R. 10 -CONR 10 R 10 -NR 10 R 10 -NR 10 CO2R 10 The optionally substituted C1-C6 alkyl group, the optionally substituted C3-C5 cycloalkyl group, the optionally substituted heterocyclic group selected from pyrrolidine, pyrrolidone, piperidine, or morpholine, the optionally substituted phenyl group, or the optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy group; and each of the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is optionally substituted with 1 to 3 substituents, each of which is independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0127] In compounds of formula (I) or (II) or their pharmaceutically acceptable salts, R2 is a bicyclic ring optionally substituted from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, indololin-2-one, or benzo[d]oxazol-2(3H)-one, or a bicyclic heteroaryl ring optionally substituted, wherein a phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to a pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; wherein the optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN Halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl is optionally substituted with -CN, -OH or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic or heteroaryl is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0128] In compounds of formula (I) or (II) or their pharmaceutically acceptable salts, R2 is a optionally substituted bicyclic ring selected from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, or benzo[d]oxazol-2(3H)-one, or an optionally substituted bicyclic heteroaryl ring, wherein a phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to a pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; wherein the optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogen, C1 -C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl is optionally substituted with -CN, -OH or C1-C3 alkoxy; wherein each optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic or heteroaryl is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0129] In compounds of formula (I) or (II) or pharmaceutically acceptable salts thereof, R2 is optionally substituted with a bicyclic ring selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one or 2,3-dihydro-[1,4]dioxacyclohexenolo[2,3-b]pyridine, or optionally substituted with a bicyclic ring selected from indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, A bicyclic heteroaryl group of imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, benzoxazole, benzothiazole, pyrrolopyrazine, quinazoline, naphthidine, quinoline, or oxazolopyridine; wherein the optionally substituted bicyclic group is optionally substituted by 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted by 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -SO2R 10 -C(O)OC1-C3 alkyl, -CONR 10 R 10 -NR 10 R 10 -NR 10 CO2R 10 -OH, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, optionally substituted 1,3-benzodioxane, optionally substituted 2,3-dihydro-1,4-benzodioxane, or optionally substituted heteroaryl selected from pyridine, pyrimidine, pyridazine, pyrazine, pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl is each optionally replaced by -CN, -OH, oxetyl, C1-C3 alkoxy, -CONR 10 R 10 Or phenyl substitution; the optionally substituted C3-C5 cycloalkyl, phenyl, 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, heterocyclic or heteroaryl group is each optionally substituted by 1 to 3 substituents, each substituent being independently selected from halogens, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -SO2R 10 -NR 10 R10 -OH or -CN.

[0130] In compounds of formula (I) or (II) or pharmaceutically acceptable salts thereof, R2 is optionally substituted with a bicyclic compound selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one or 2,3-dihydro-[1,4]dioxacyclohexenolo[2,3-b]pyridine, or optionally substituted with a bicyclic compound selected from indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazole The bicyclic heteroaryl group of pyrimidine, imidazopyridazine, phthalazine, triazolidine, benzimidazole, pyrrolopyrimidine, thiazopyridazine, benzotriazole, benzoxazole, benzothiazole, pyrrolopyrazine, quinazoline, or naphthidine; wherein the optionally substituted bicyclic group is optionally substituted by 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl group is optionally substituted by 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -SO2R 10 -CONR 10 R 10 -NR 10 R 10 -NR 10 CO2R 10 Optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 ynyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, optionally substituted 1,3-benzodioxane, optionally substituted 2,3-dihydro-1,4-benzodioxane, or optionally substituted heteroaryl selected from pyridine, pyrimidine, pyridazine, pyrazine, pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein... The optionally substituted C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl groups are each optionally substituted with -CN, -OH, oxetyl, or C1-C3 alkoxy groups; the optionally substituted C3-C5 cycloalkyl, phenyl, 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, heterocyclic, or heteroaryl groups are each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens, C1-C3 alkyl groups, C1-C3 haloalkyl groups, C1-C3 alkoxy groups, C1-C3 haloalkoxy groups, and -SO2R groups. 10 -NR 10 R 10-OH or -CN.

[0131] In yet another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R2 is optionally substituted from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one or 2,3-dihydro-[1,4]dioxacyclohexenolo[2,3-b]pyridin-2-one. The pyridine bicyclic ring, or optionally substituted with a bicyclic heteroaryl group selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, benzoxazole, benzothiazole, pyrrolopyrazine, or quinazoline; wherein the optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6. Alkyl group; the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocycle selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heterocycle selected from pyrazole. The heteroaryl group of isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0132] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R2 is optionally substituted with a bicyclic compound selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, indololin-2-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted with a compound selected from indole, indazole, pyrrolopyridine, furanopyridine, or pyrazolopyridine. A bicyclic heteroaryl group of imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, or benzoxazole; wherein the optionally substituted bicyclic group is optionally substituted by 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl group is optionally substituted by 1 to 3 substituents, the substitutions being... Each of the substituents is independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl is optionally substituted with -CN, -OH or C1-C3 alkoxy; the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic or heteroaryl is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0133] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R2 is a bicyclic ring optionally substituted from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one or benzo[d]oxazol-2(3H)-one, or optionally substituted from a bicyclic heteroaryl group selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine or phthalazine; wherein the optionally substituted bicyclic ring is optionally substituted by 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted by 1 to 3 substituents, each substituent being independently selected from -CN, halogen, C1-C6 halogenated groups. Alkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl is optionally substituted with -CN, -OH or C1-C3 alkoxy; wherein each optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic or heteroaryl is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0134] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R2 is optionally substituted with a bicyclic ring selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindoline-1-one, indoline-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one or 2,3-dihydro-[1,4]dioxacyclohexen[2,3-b]pyridine, or optionally substituted with a bicyclic ring selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, benzoxazole The bicyclic heteroaryl group of benzothiazole, pyrrolopyrazine, quinazoline, or naphthidine (preferably indole, indazole, pyrrolopyrazine, furanopyrazine, pyrazolopyrazine, imidazopyrazine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyrazine, benzimidazole, pyrrolopyrimidine, thiazopyrazine, benzotriazole, benzoxazole, benzothiazole, pyrrolopyrazine, or quinazoline); wherein the optionally substituted bicyclic group is optionally substituted by 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl group is optionally substituted by 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -SO2R 10 -CONR 10 R 10 -NR 10 R 10 -NR 10 CO2R 10Optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 ynyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, optionally substituted 1,3-benzodioxane, optionally substituted 2,3-dihydro-1,4-benzodioxane, or optionally substituted heteroaryl selected from pyridine, pyrimidine, pyridazine, pyrazine, pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein... The optionally substituted C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl groups are each optionally substituted with -CN, -OH, oxetyl, or C1-C3 alkoxy groups; the optionally substituted C3-C5 cycloalkyl, phenyl, 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, heterocyclic, or heteroaryl groups are each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens, C1-C3 alkyl groups, C1-C3 haloalkyl groups, C1-C3 alkoxy groups, C1-C3 haloalkoxy groups, and -SO2R groups. 10 -NR 10 R 10 -OH or -CN; preferably, the optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; and the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl groups, C1-C6 alkoxy groups, C1-C6 alkyl groups optionally substituted with -OH or oxobutyl groups, or heteroaryl groups selected from pyridine or oxazole.

[0135] In another embodiment of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R2 is optionally substituted with a compound selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one, or 2,3-dihydro-[1,4]dioxacyclohexene. The bicyclic ring of pyridine [2,3-b]pyridine, or optionally substituted with a ring selected from indole, inazole, pyrrolo[2,3-b]pyridine, pyrrolo[3,2-b]pyridine, furano[2,3-c]pyridine, furano[3,2-c]pyridine, pyrazolo[1,5-a]pyridine, pyrazolo[3,4-b]pyridine, pyrazolo[3,4-c]pyridine, pyrazolo[4,3-b]pyridine, imidazo[1,2-a]pyridine, imidazo[1,5-b]pyridine, etc. [-a]pyridine, pyrazolo[1,5-a]pyrimidine, imidazo[1,2-b]pyridazine, phthalazine, [1,2,4]triazolo[4,3-a]pyridine, triazolo[1,5-a]pyridine, benzimidazole, pyrrolo[2,3-d]pyrimidine, thiazo[5,4-b]pyridine, benzotriazole, 1,3-benzoxazole, 1,3-benzothiazole, pyrrolo[1,2-a]pyrazine, quinazoline, 1,5-naphthidine, 1,7-naphthidine A bicyclic heteroaryl group of quinoline or oxazolo[5,4-b]pyridine; wherein the optionally substituted bicyclic group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -SO2R 10 -C(O)OC1-C3 alkyl, -CONR 10 R 10 -NR 10 R 10 -NR 10 CO2R 10-OH, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, optionally substituted 1,3-benzodioxane, optionally substituted 2,3-dihydro-1,4-benzodioxane, or optionally substituted heteroaryl selected from pyridine, pyrimidine, pyridazine, pyrazine, pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl is each optionally replaced by -CN, -OH, oxetyl, C1-C3 alkoxy, -CONR 10 R 10 Or phenyl substitution; the optionally substituted C3-C5 cycloalkyl, phenyl, 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, heterocyclic or heteroaryl group is each optionally substituted by 1 to 3 substituents, each substituent being independently selected from halogens, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -SO2R 10 -NR 10 R 10 -OH or -CN.

[0136] In another embodiment of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R2 is optionally substituted with a compound selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one or 2,3-dihydro-[1,4]dioxazol-2(3H)-one. The bicyclic oxacyclohexen[2,3-b]pyridine, or optionally substituted with a compound selected from indole, indazole, pyrrolo[2,3-b]pyridine, pyrrolo[3,2-b]pyridine, furano[2,3-c]pyridine, furano[3,2-c]pyridine, pyrazolo[1,5-a]pyridine, pyrazolo[3,4-b]pyridine, pyrazolo[3,4-c]pyridine, pyrazolo[4,3-b]pyridine, imidazo[1,2-a]pyridine, or oxacyclohexen[2,3-b]pyridine. Pyridine, imidazo[1,5-a]pyridine, pyrazolo[1,5-a]pyrimidine, imidazo[1,2-b]pyridazine, phthalazine, [1,2,4]triazolo[4,3-a]pyridine, triazolo[1,5-a]pyridine, benzimidazole, pyrrolo[2,3-d]pyrimidine, thiazo[5,4-b]pyridine, benzotriazole, 1,3-benzoxazole, 1,3-benzothiazole, pyrrolo[1,2-a]pyrazine, quinazole A bicyclic heteroaryl group of porphyrin or 1,7-naphthidine; wherein the optionally substituted bicyclic group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; and the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl groups, C1-C6 alkoxy groups, C1-C6 haloalkoxy groups, -SO2R 10 -CONR 10 R 10 -NR 10 R 10 -NR 10 CO2R 10Optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 ynyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, optionally substituted 1,3-benzodioxane, optionally substituted 2,3-dihydro-1,4-benzodioxane, or optionally substituted heteroaryl selected from pyridine, pyrimidine, pyridazine, pyrazine, pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein... The optionally substituted C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl groups are each optionally substituted with -CN, -OH, oxetyl, or C1-C3 alkoxy groups; the optionally substituted C3-C5 cycloalkyl, phenyl, 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, heterocyclic, or heteroaryl groups are each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens, C1-C3 alkyl groups, C1-C3 haloalkyl groups, C1-C3 alkoxy groups, C1-C3 haloalkoxy groups, and -SO2R groups. 10 -NR 10 R 10 -OH or -CN; preferably, the optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; and the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl groups, C1-C6 alkoxy groups, C1-C6 alkyl groups optionally substituted with -OH or oxobutyl groups, or heteroaryl groups selected from pyridine or oxazole.

[0137] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R2 is a group of the following formula:

[0138]

[0139]

[0140]

[0141]

[0142]

[0143] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R2 is a group of the following formula:

[0144]

[0145]

[0146]

[0147]

[0148] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, halogen, -CN, -N(H)(CH2CH2CO2H), -C(O)C1-C3 alkyl, C1-C6 alkyl, C1-C6 haloalkyl, oxetane, isoxazole, or pyridine (preferably 3-pyridine). In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, halogen, -CN, C1-C6 alkyl, C1-C6 haloalkyl, C3-C5 cycloalkyl, a heterocycle containing 3 to 5 ring atoms of 1, 2, or 3 ring heteroatoms independently selected from N, O, or S, or a heteroaryl group containing 5 ring atoms of 1, 2, or 3 ring heteroatoms independently selected from N, O, or S. In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, halogen, -CN, C1-C6 alkyl, C1-C6 haloalkyl, oxetane, or isoxazole. In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, -CN, C1-C6 alkyl, or C1-C6 haloalkyl; preferably, R3 is -H, -CN, C1-C3 alkyl, or C1-C3 haloalkyl; more preferably, R3 is -H, -CN, or C1-C3 alkyl; most preferably, R3 is -H or methyl. Also preferably, R3 is -H, methyl, or trifluoromethyl.

[0149] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R4 is H or a halogen, preferably R4 is -H.

[0150] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R5 is -H, halogen, C1-C3 alkyl or C1-C3 haloalkyl; more preferably, R5 is -H, halogen, methyl or trifluoromethyl.

[0151] In another compound of formula (I) or (II) or its pharmaceutically acceptable salt, R6 is -H or a halogen.

[0152] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, -CN, C1-C3 alkyl, or C1-C3 haloalkyl (preferably, R3 is -H, -CN, or C1-C3 alkyl), and R2 is optionally substituted from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridine- A bicyclic ring of 2-one or 2,3-dihydro-[1,4]dioxane-[2,3-b]pyridine (preferably 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, indololin-2-one, or benzo[d]oxazol-2(3H)-one), or optionally a substituted bicyclic heteroaryl ring, wherein the phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to the pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; wherein the The optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocycles selected from pyrrolidine, pyrrolidone, piperidine, or morpholine, and any The substituted phenyl group, or optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole, isoaryl group; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy group; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0153] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, -CN, C1-C3 alkyl, or C1-C3 haloalkyl (preferably, R3 is -H, -CN, or C1-C3 alkyl), and R2 is optionally substituted with a compound selected from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, or benzo[d]oxazol-2(3H). A bicyclic ring of a ketone, or optionally a substituted bicyclic heteroaryl group, wherein a phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to a pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; wherein the optionally substituted bicyclic ring is optionally substituted by 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted by 1 to 3 substituents. Each substituent is selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl is optionally substituted with -CN, -OH or C1-C3 alkoxy; each optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic or heteroaryl is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0154] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, methyl, or trifluoromethyl (preferably, R3 is -H or methyl), and R2 is optionally substituted from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one, or 2,3-dihydro-[1,4]dioxane-[2,3-b]pyridine (preferably 1,3-benzodioxane). Bicyclic compounds of indole, 2,3-dihydro-1,4-benzodioxane, isoindoline-1-one, indoline-2-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted with a group selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, benzoxazole, benzothiazole, pyrrolopyrazine, or quinazoline (preferably indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine). A bicyclic heteroaryl group of phthalazine, triazolidine, benzimidazole, pyrrolopyrimidine, thiazopyrimidine, benzotriazole, or benzoxazole; wherein the optionally substituted bicyclic group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted... The substituted C1-C6 alkyl group is selected from pyrrolidine, pyrrolidone, piperidine, or morpholine; optionally substituted phenyl group; or optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy group; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0155] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, methyl, or trifluoromethyl (preferably, R3 is -H or methyl), and R2 is a bicyclic ring optionally substituted from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, or benzo[d]oxazol-2(3H)-one, or a bicyclic heteroaryl ring optionally substituted from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, or phthalazine; wherein the optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from... -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl is optionally substituted with -CN, -OH or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic or heteroaryl is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0156] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R4 is -H or a halogen (preferably, R4 is -H), and R2 is optionally substituted from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one or 2,3-dihydro-[1,4]dioxane[ 2,3-b]pyridine (preferably 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, indololin-2-one, or benzo[d]oxazol-2(3H)-one) bicyclic, or optionally substituted bicyclic heteroaryl, wherein the phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to the pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; wherein the optionally substituted bicyclic ring is optionally 1 to The alternatively substituted bicyclic heteroaryl group is substituted with 1 to 3 substituents, each of which is independently selected from halogens and C1-C6 alkyl groups; the alternatively substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each of which is independently selected from -CN, halogens, C1-C6 haloalkyl groups, C1-C6 alkoxy groups, C1-C6 haloalkoxy groups, alternatively substituted C1-C6 alkyl groups, alternatively substituted C3-C5 cycloalkyl groups, alternatively substituted heterocycles selected from pyrrolidine, pyrrolidone, piperidine, or morpholine, and alternatively substituted phenyl groups. The C1-C6 alkyl group may be optionally substituted with a heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR. 10 R 10 -OH or -CN.

[0157] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R4 is -H or a halogen (preferably, R4 is -H), and R2 is a bicyclic ring optionally substituted from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, or benzo[d]oxazol-2(3H)-one, or a bicyclic heteroaryl ring optionally substituted, wherein a phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to a pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; wherein the optionally substituted bicyclic ring is optionally substituted by 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl ring is optionally substituted by 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups. The radical is selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl is optionally substituted with -CN, -OH or C1-C3 alkoxy; wherein each optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic or heteroaryl is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0158] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R4 is -H or a halogen (preferably, R4 is -H), and R2 is optionally substituted from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one or 2,3-dihydro-[1,4]dioxane-1-[2,3-b]pyridine (preferably 1,3-benzodioxane, 2,3- Dihydro-1,4-benzodioxane, isoindoline-1-one, indoline-2-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted with a bicyclic compound selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, benzoxazole, benzothiazole, pyrrolopyridazine, or quinazoline (preferably indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridazine, benzotriazole, benzoxazole, benzothiazole, pyrrolopyridazine, or quinazoline) A bicyclic heteroaryl group of azole pyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, or benzoxazole; wherein the optionally substituted bicyclic group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted... The heterocyclic group selected from pyrrolidine, pyrrolidone, piperidine, or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0159] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R4 is -H or a halogen (preferably, R4 is -H), and R2 is a bicyclic ring optionally substituted from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one or benzo[d]oxazol-2(3H)-one, or optionally substituted from a bicyclic heteroaryl ring selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine or phthalazine; wherein the optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, Halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl is optionally substituted with -CN, -OH or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic or heteroaryl is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0160] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R5 is -H, halogen, C1-C3 alkyl, or C1-C3 haloalkyl, and R2 is optionally substituted with a compound selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one, or 2,3-dihydro-[1,4]dioxacyclopentene. A bicyclic heteroaryl group of heterocyclohexen[2,3-b]pyridine (preferably 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, indololin-2-one, or benzo[d]oxazol-2(3H)-one), or optionally substituted bicyclic heteroaryl group, wherein the phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to a pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; wherein the optionally substituted bicyclic ring is optionally... The substituted bicyclic heteroaryl group is substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl groups, C1-C6 alkoxy groups, C1-C6 haloalkoxy groups, optionally substituted C1-C6 alkyl groups, optionally substituted C3-C5 cycloalkyl groups, optionally substituted heterocycles selected from pyrrolidine, pyrrolidone, piperidine, or morpholine, optionally substituted... The alkyl group is phenyl, or optionally substituted with a heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR. 10 R 10 -OH or -CN.

[0161] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R5 is -H, halogen, C1-C3 alkyl, or C1-C3 haloalkyl, and R2 is optionally substituted bicyclic selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted bicyclic heteroaromatic. The bicyclic ring, wherein a phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to a pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; wherein the optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, the substituents being... Each of the following is independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl is optionally substituted with -CN, -OH or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic or heteroaryl is each optionally substituted with 1 to 3 substituents, each of which is independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0162] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R5 is -H, halogen, methyl, or trifluoromethyl, and R2 is optionally substituted from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one, or 2,3-dihydro-[1,4]dioxane-[2,3-b]pyridine (preferably 1,3-benzodioxane, 2,3-dihydro- 1,4-Benzadioxazine, isoindoline-1-one, indoline-2-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted with a bicyclic compound selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, benzoxazole, benzothiazole, pyrrolopyridine, pyrrolopyridine, or quinazoline (preferably indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine). A bicyclic heteroaryl group of pyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, or benzoxazole; wherein the optionally substituted bicyclic group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted... Heterocyclic compounds of pyrrolidine, pyrrolidone, piperidine, or morpholine, optionally substituted phenyl groups, or optionally substituted heteroaryl groups selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy groups; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0163] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R5 is -H, halogen, methyl, or trifluoromethyl, and R2 is a bicyclic ring optionally substituted from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, or benzo[d]oxazol-2(3H)-one, or a bicyclic heteroaryl ring optionally substituted from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, or phthalazine; wherein the optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogen, methyl, trifluoromethyl, or trifluoromethyl groups. The alkyl group comprises a halogen, a C1-C6 haloalkyl group, a C1-C6 alkoxy group, a C1-C6 haloalkoxy group, a optionally substituted C1-C6 alkyl group, an optionally substituted C3-C5 cycloalkyl group, an optionally substituted heterocyclic group selected from pyrrolidine, pyrrolidone, piperidine, or morpholine, an optionally substituted phenyl group, or an optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; and each of the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is optionally substituted with 1 to 3 substituents, each of which is independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR. 10 R 10 -OH or -CN.

[0164] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R6 is -H or a halogen, and R2 is optionally substituted from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one, or 2,3-dihydro-[1,4]dioxacyclohexeno[2,3-b]pyridine A bicyclic ring (preferably 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, indololin-2-one, or benzo[d]oxazol-2(3H)-one), or optionally a substituted bicyclic heteroaryl ring, wherein a phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to a pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; wherein the optionally substituted bicyclic ring is optionally substituented by 1 to 3 substituents. The substitution is made by substituents, each independently selected from halogens and C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl group is optionally substituted by 1 to 3 substituents, each independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocycles selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or... Optionally substituted heteroaryl groups selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0165] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R6 is -H or a halogen, and R2 is a bicyclic ring optionally substituted from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one or benzo[d]oxazol-2(3H)-one, or a bicyclic heteroaryl ring optionally substituted, wherein a phenyl, pyridine, pyrazine, pyrimidine or pyridazine ring is fused to a pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine or pyridazine ring; wherein the optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -C1-C6 alkyl groups. N, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl is optionally substituted with -CN, -OH or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic or heteroaryl is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0166] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R6 is -H or a halogen, and R2 is optionally substituted from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one or 2,3-dihydro-[1,4]dioxane-2,3-b]pyridine (preferably 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane). The bicyclic ring of dioxazolene, isoindoline-1-one, indoline-2-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted with a ring selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, benzoxazole, benzothiazole, pyrrolopyridine, or quinazoline (preferably indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine). The bicyclic heteroaryl group of benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, or benzoxazole; wherein the optionally substituted bicyclic group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted from pyrrolopyrimidine, etc. The heterocyclic compound of pyrrolidone, piperidine, or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0167] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R6 is -H or a halogen, and R2 is a bicyclic ring optionally substituted from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one or benzo[d]oxazol-2(3H)-one, or a bicyclic heteroaryl ring optionally substituted from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine or phthalazine; wherein the optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogen, C1 -C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl is optionally substituted with -CN, -OH or C1-C3 alkoxy; wherein each optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic or heteroaryl is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0168] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, -CN, C1-C3 alkyl or C1-C3 haloalkyl, and R4 is H or halogen; more preferably, R3 is -H, -CN or C1-C3 alkyl, and R4 is H; most preferably, R3 is -H or methyl, and R4 is -H.

[0169] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, -CN, C1-C3 alkyl or C1-C3 haloalkyl (preferably, R3 is -H, -CN or C1-C3 alkyl), and R5 is -H, halogen, C1-C3 alkyl or C1-C3 haloalkyl; more preferably, R3 is -H or methyl, and R5 is -H, halogen, methyl or trifluoromethyl.

[0170] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, -CN, C1-C3 alkyl or C1-C3 haloalkyl (preferably, R3 is -H, -CN or C1-C3 alkyl), and R6 is -H or halogen; more preferably, R3 is -H or methyl, and R6 is -H or halogen.

[0171] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R4 is -H or a halogen (preferably, R4 is -H), and R5 is -H, a halogen, a C1-C3 alkyl or a C1-C3 haloalkyl; preferably, R5 is -H, a halogen, a methyl or trifluoromethyl.

[0172] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R4 is -H or a halogen (preferably, R4 is -H) and R6 is -H or a halogen.

[0173] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R5 is -H, halogen, C1-C3 alkyl or C1-C3 haloalkyl, and R6 is -H or halogen; preferably, R5 is -H, halogen, methyl or trifluoromethyl, and R6 is -H.

[0174] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, -CN, C1-C3 alkyl, or C1-C3 haloalkyl (preferably, R3 is -H, -CN, or C1-C3 alkyl), R4 is -H or halogen (preferably, R4 is -H), and R2 is optionally substituted from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2 H-pyrrolo[2,3-b]pyridin-2-one or 2,3-dihydro-[1,4]dioxane-hexenolo[2,3-b]pyridine (preferably 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, indololin-2-one or benzo[d]oxazol-2(3H)-one) bicyclic, or optionally substituted bicyclic heteroaryl, wherein the phenyl, pyridine, pyrazine, pyrimidine or pyridazine ring is fused to pyrrole, furan, thiophene, pyrazole, isoxazol, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, The pyrimidine or pyridazine ring; wherein the optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted pyrrolidine, pyrrolidone, piperidine, or morpholine. The heterocyclic, optionally substituted phenyl, or optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10-OH or -CN; preferably, R3 is -H or methyl, R4 is -H, and R2 is optionally substituted with a compound selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindoline-1-one, indoline-2-one, or benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one, or 2,3-dihydro-[1,4]dioxacyclohexeno[2,3-b]pyridine (preferably 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene). The bicyclic ring of isoindoline-1-one, indoline-2-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted with a ring selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, benzoxazole, benzothiazole, pyrrolopyrazine, or quinazoline (preferably indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole) The bicyclic heteroaryl group of pyrrolopyrimidine, thiazopyridine, benzotriazole, or benzoxazole; wherein the optionally substituted bicyclic group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted alkyl group selected from pyrroloidine, etc. The heterocycle of pyrrolidone, piperidine, or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocycle, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0175] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, -CN, C1-C3 alkyl, or C1-C3 haloalkyl (preferably, R3 is -H, -CN, or C1-C3 alkyl), R4 is -H or halogen (preferably, R4 is -H), and R2 is optionally substituted with a compound selected from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoyindoline-1- A bicyclic ring of a ketone or benzo[d]oxazol-2(3H)-one, or optionally a substituted bicyclic heteroaryl ring, wherein a phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to a pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; wherein the optionally substituted bicyclic ring is optionally substituted by 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; the optionally substituted bicyclic ring The heteroaryl group is optionally substituted with 1 to 3 substituents, each of which is independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocycle selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heterocycle selected from pyrazole, isoxazole, isothiazole. The C1-C6 alkyl group is a heteroaryl group of imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR. 10 R 10-OH or -CN; preferably, R3 is -H or methyl, R4 is -H, and R2 is a bicyclic ring optionally substituted from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one or benzo[d]oxazol-2(3H)-one, or a bicyclic heteroaryl ring optionally substituted from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine or phthalazine; wherein the optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogen, C1-C6 halogenated... Alkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl is optionally substituted with -CN, -OH or C1-C3 alkoxy; wherein each optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic or heteroaryl is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0176] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, -CN, C1-C3 alkyl, or C1-C3 haloalkyl (preferably, R3 is -H, -CN, or C1-C3 alkyl), and R2 is optionally substituted from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridine- A bicyclic ring of 2-one or 2,3-dihydro-[1,4]dioxane-[2,3-b]pyridine (preferably 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, indololin-2-one, or benzo[d]oxazol-2(3H)-one), or optionally a substituted bicyclic heteroaryl ring, wherein the phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to the pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; wherein the The optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocycles selected from pyrrolidine, pyrrolidone, piperidine, or morpholine, and any The substituted phenyl group, or optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole, isoaryl group; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy group; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10-OH or -CN; preferably, R3 is -H or methyl, R5 is -H, halogen, methyl or trifluoromethyl, and R2 is optionally substituted with a compound selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one or 2,3-dihydro-[1,4]dioxacyclohexen[2,3-b]pyridine (preferably 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, 2,3 ... The bicyclic ring of dioxane, isoindoline-1-one, indoline-2-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted with a ring selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, benzoxazole, benzothiazole, pyrrolopyridine, or quinazoline (preferably indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine). A bicyclic heteroaryl group of benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, or benzoxazole; wherein the optionally substituted bicyclic group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted from... The heterocyclic form of pyrrolidine, pyrrolidone, piperidine, or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0177] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, -CN, C1-C3 alkyl, or C1-C3 haloalkyl (preferably, R3 is -H, -CN, or C1-C3 alkyl), and R2 is optionally substituted with a compound selected from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, or benzo[d]oxazol-2(3H). A bicyclic ring of a ketone, or optionally a substituted bicyclic heteroaryl group, wherein a phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to a pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; wherein the optionally substituted bicyclic ring is optionally substituted by 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted by 1 to 3 substituents. Each substituent is selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl is optionally substituted with -CN, -OH or C1-C3 alkoxy; each optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic or heteroaryl is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10R3 is -H or -CN; preferably, R5 is -H, halogen, methyl, or trifluoromethyl, and R2 is a bicyclic ring optionally substituted from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, or benzo[d]oxazol-2(3H)-one, or a bicyclic heteroaryl ring optionally substituted from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, or phthalazine; wherein the optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogen, C1... -C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl is optionally substituted with -CN, -OH or C1-C3 alkoxy; wherein each optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic or heteroaryl is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0178] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, -CN, C1-C3 alkyl or C1-C3 haloalkyl (preferably, R3 is -H, -CN or C1-C3 alkyl), R6 is -H or halogen, and R2 is optionally substituted from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3] [-b]pyridin-2-one or 2,3-dihydro-[1,4]dioxane-1-one, indolin-2-one or benzo[d]oxazol-2(3H)-one, a bicyclic ring of pyrrole, furan, thiophene, pyrazole, isoxazol-2-one or benzo[d]oxazol-2(3H)-one, or optionally a substituted bicyclic heteroaryl group, wherein the phenyl, pyridine, pyrazine, pyrimidine or pyridazine ring is fused to the pyrrole, furan, thiophene, pyrazole, isoxazol, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine or pyridazine ring. The optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic rings selected from pyrrolidine, pyrrolidone, piperidine, or morpholine. Optionally substituted phenyl groups, or optionally substituted heteroaryl groups selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy groups; wherein each optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10-OH or -CN; preferably, R3 is -H or methyl, R6 is -H, and R2 is optionally substituted with a compound selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one or 2,3-dihydro-[1,4]dioxacyclohexen[2,3-b]pyridine (preferably 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, ... A bicyclic ring of isoindoline-1-one, indoline-2-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted with a ring selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, benzoxazole, benzothiazole, pyrrolopyrazine, or quinazoline (preferably indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrazolopyridine). A bicyclic heteroaryl group of pyrrolidine, thiazopyridine, benzotriazole, or benzoxazole; wherein the optionally substituted bicyclic group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted pyrrolidine. The C1-C6 alkyl group is a heterocyclic compound of pyrrolidone, piperidine, or morpholine, optionally substituted with a phenyl group, or optionally substituted with a heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR. 10 R 10 -OH or -CN.

[0179] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, -CN, C1-C3 alkyl, or C1-C3 haloalkyl (preferably, R3 is -H, -CN, or C1-C3 alkyl), R6 is -H or halogen, and R2 is optionally substituted with a compound selected from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, or benzo[d]oxazole. A bicyclic ring of a -2(3H)-one, or optionally a substituted bicyclic heteroaryl group, wherein a phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to a pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; wherein the optionally substituted bicyclic ring is optionally substituted by 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl group is optionally... It is substituted with 1 to 3 substituents, each of which is independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocycles selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted pyrazole, isoxazole, isothiazole, imidazole The heteroaryl group of oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10-OH or -CN; preferably, R3 is -H or methyl, R6 is -H, and R2 is a bicyclic ring optionally substituted from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one or benzo[d]oxazol-2(3H)-one, or a bicyclic heteroaryl ring optionally substituted from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine or phthalazine; wherein the optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogen, C1-C6 halogenated... Alkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl is optionally substituted with -CN, -OH or C1-C3 alkoxy; wherein each optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic or heteroaryl is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0180] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R4 is -H or a halogen (preferably, R4 is -H), R5 is -H, a halogen, a C1-C3 alkyl or a C1-C3 haloalkyl, and R2 is optionally substituted from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one. Or a bicyclic ring of 2,3-dihydro-[1,4]dioxane-[2,3-b]pyridine (preferably 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, indololin-2-one, or benzo[d]oxazol-2(3H)-one), or optionally a substituted bicyclic heteroaryl ring, wherein the phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to a pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; wherein any The optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocycles selected from pyrrolidine, pyrrolidone, piperidine, or morpholine, optionally... The substituted phenyl group, or optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10-OH or -CN; preferably, R5 is -H, halogen, methyl or trifluoromethyl, and R2 is optionally substituted with a compound selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindoline-1-one, indoline-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one or 2,3-dihydro-[1,4]dioxacyclohexen[2,3-b]pyridine (preferably 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene). The bicyclic compound of an alkene, isoindoline-1-one, indoline-2-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted with a compound selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, benzoxazole, benzothiazole, pyrrolopyrazine, or quinazoline (preferably indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole). A bicyclic heteroaryl group of azole, pyrrolopyrimidine, thiazopyridine, benzotriazole, or benzoxazole; wherein the optionally substituted bicyclic group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted pyrroloalkyl. The C1-C6 alkyl group is a heterocyclic compound of pyrrolidone, piperidine, or morpholine, optionally substituted with a phenyl group, or optionally substituted with a heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR. 10 R 10 -OH or -CN.

[0181] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R4 is -H or a halogen (preferably, R4 is -H), R5 is -H, a halogen, a C1-C3 alkyl group, or a C1-C3 haloalkyl group, and R2 is optionally substituted with a compound selected from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, or benzo[d]oxazol-2(3H)-one. A bicyclic, or optionally substituted, bicyclic heteroaryl, wherein a phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to a pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; wherein the optionally substituted bicyclic is optionally substituted by 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl is optionally substituted by 1 to 3 substituents. The substituents are each independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl is optionally substituted with -CN, -OH or C1-C3 alkoxy; the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic or heteroaryl is each optionally substituted with 1 to 3 substituents, each independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10-OH or -CN; preferably, R5 is -H, halogen, methyl or trifluoromethyl, and R2 is a bicyclic ring optionally substituted from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one or benzo[d]oxazol-2(3H)-one, or a bicyclic heteroaryl ring optionally substituted from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine or phthalazine; wherein the optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogen, C1-C6 alkyl groups. The C1-C6 alkyl group, C1-C6 alkoxy group, C1-C6 haloalkoxy group, optionally substituted C1-C6 alkyl group, optionally substituted C3-C5 cycloalkyl group, optionally substituted heterocyclic group selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl group, or optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH or C1-C3 alkoxy group; wherein the optionally substituted C3-C5 cycloalkyl group, phenyl group, heterocyclic group or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl group, C1-C3 haloalkyl group, C1-C3 alkoxy group, C1-C3 haloalkoxy group, -NR group. 10 R 10 -OH or -CN.

[0182] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R4 is -H or a halogen (preferably, R4 is -H), R6 is -H or a halogen, and R2 is optionally substituted with a compound selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one, or 2,3-dihydro-[1,4]dioxazol-2-one. The bicyclic ring of oxacyclohexen[2,3-b]pyridine (preferably 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, indololin-2-one, or benzo[d]oxazol-2(3H)-one), or optionally a substituted bicyclic heteroaryl ring, wherein the phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to the pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; wherein the optionally substituted bicyclic ring is... The substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl groups, C1-C6 alkoxy groups, C1-C6 haloalkoxy groups, optionally substituted C1-C6 alkyl groups, optionally substituted C3-C5 cycloalkyl groups, optionally substituted heterocycles selected from pyrrolidine, pyrrolidone, piperidine, or morpholine, optionally substituted... The phenyl group, or optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10-OH or -CN; preferably, R4 and R6 are each -H, and R2 is optionally substituted with a compound selected from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindoline-1-one, indoline-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one or 2,3-dihydro-[1,4]dioxane-1-[2,3-b]pyridine (preferably 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindoline-1-one, indoline-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridine). A bicyclic ring of 1-line-one, indoline-2-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted with a ring selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, benzoxazole, benzothiazole, pyrrolopyrazine, or quinazoline (preferably indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyridine). A bicyclic heteroaryl group of pyrimidine, thiazopyridine, benzotriazole, or benzoxazole; wherein the optionally substituted bicyclic group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted pyrrolidine, The heterocycle of pyrrolidone, piperidine, or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocycle, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0183] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R4 is -H or a halogen (preferably, R4 is -H), R6 is -H or a halogen, and R2 is optionally substituted bicyclic selected from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one or benzo[d]oxazol-2(3H)-one, or optionally substituted bicyclic heterocyclic An aryl group, wherein a phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to a pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; wherein the optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, the substitution... Each of the substituents is independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl is optionally substituted with -CN, -OH or C1-C3 alkoxy; the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic or heteroaryl is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10-OH or -CN; preferably, R4 and R6 are each -H, and R2 is a bicyclic ring optionally substituted from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one or benzo[d]oxazol-2(3H)-one, or optionally substituted from a bicyclic heteroaryl ring selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine or phthalazine; wherein the optionally substituted bicyclic ring is optionally substituted by 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl ring is optionally substituted by 1 to 3 substituents, each substituent being independently selected from -CN, halogen, C1-C6 haloalkyl groups. C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl is optionally substituted with -CN, -OH or C1-C3 alkoxy; wherein each optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic or heteroaryl is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0184] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R5 is -H, halogen, C1-C3 alkyl, or C1-C3 haloalkyl, R6 is -H or halogen, and R2 is optionally substituted with a compound selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one, or 2,3-dihydro-[ [1,4]dioxane-[2,3-b]pyridine (preferably 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, indololin-2-one, or benzo[d]oxazol-2(3H)-one) bicyclic, or optionally substituted bicyclic heteroaryl, wherein the phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to the pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; wherein the optionally substituted ring is... The bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocycles selected from pyrrolidine, pyrrolidone, piperidine, or morpholine, optionally substituted... The substituted phenyl group, or optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10-OH or -CN; preferably, R5 is -H, halogen, methyl or trifluoromethyl, R6 is -H, and R2 is optionally substituted with a compound selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one or 2,3-dihydro-[1,4]dioxacyclohexen[2,3-b]pyridine (preferably 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, 2,3-dihydro-1,4-benzodioxacyclohexene, 2,3-dihydro-1,4-benzodioxacyclohexene, 2,3-dihydro-1,4-benzodioxacyclohexene, 2,3-dihydro-1,4-benzodioxacyclohexene, 2,3-dihydro-2,4-benzodioxacyclohexene, 2,3-dihydro-1,4-benzodioxacyclohexene, 2,3-dihydro-2,4-dihydro-2,3 ... The bicyclic ring of oxacyclohexene, isoindoline-1-one, indoline-2-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted with a ring selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, benzoxazole, benzothiazole, pyrrolopyrazine, or quinazoline (preferably indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzo[d]oxazol ... A bicyclic heteroaryl group of imidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, or benzoxazole; wherein the optionally substituted bicyclic group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted from pyrrolopyrimidine, etc. The heterocyclic compound of pyrrolidone, piperidine, or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0185] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R5 is -H, halogen, C1-C3 alkyl, or C1-C3 haloalkyl, R6 is -H or halogen, and R2 is optionally substituted with a bicyclic compound selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted with a bicyclic compound of the same type. A substituted bicyclic heteroaryl group, wherein a phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to a pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; wherein the optionally substituted bicyclic group is optionally substituted by 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl group is optionally substituted by 1 to 3 substituents, wherein... Each of the substituents is independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl is optionally substituted with -CN, -OH or C1-C3 alkoxy; each of the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic or heteroaryl is optionally substituted with 1 to 3 substituents, each of which is independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10-OH or -CN; preferably, R5 is -H, halogen, methyl or trifluoromethyl, R6 is -H, and R2 is a bicyclic ring optionally substituted from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindoline-1-one or benzo[d]oxazol-2(3H)-one, or a bicyclic heteroaryl ring optionally substituted from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine or phthalazine; wherein the optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogen, C1- C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl is optionally substituted with -CN, -OH or C1-C3 alkoxy; wherein each optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic or heteroaryl is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0186] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, -CN, C1-C3 alkyl or C1-C3 haloalkyl (preferably, R3 is -H, -CN or C1-C3 alkyl), R4 is -H or halogen (preferably, R4 is -H), and R5 is -H, halogen, C1-C3 alkyl or C1-C3 haloalkyl; more preferably, R3 is -H or methyl, R4 is -H, and R5 is -H, halogen, methyl or trifluoromethyl.

[0187] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, -CN, C1-C3 alkyl or C1-C3 haloalkyl (preferably, R3 is -H, -CN or C1-C3 alkyl), R4 is -H or halogen (preferably, R4 is -H), and R6 is -H or halogen; more preferably, R3 is -H or methyl, and R4 and R6 are each -H.

[0188] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, -CN, C1-C3 alkyl or C1-C3 haloalkyl (preferably, R3 is -H, -CN or C1-C3 alkyl), R5 is -H, halogen, C1-C3 alkyl or C1-C3 haloalkyl, and R6 is -H or halogen; more preferably, R3 is -H or methyl, R5 is -H, halogen, methyl or trifluoromethyl, and R6 is -H.

[0189] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R5 is -H, halogen, C1-C3 alkyl or C1-C3 haloalkyl, R4 is -H or halogen (preferably, R4 is -H), and R6 is -H or halogen; preferably, R5 is -H, halogen, methyl or trifluoromethyl, and R4 and R6 are each -H.

[0190] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, -CN, C1-C3 alkyl, or C1-C3 haloalkyl (preferably, R3 is -H, -CN, or C1-C3 alkyl), R4 is -H or halogen (preferably, R4 is -H), and R2 is optionally substituted from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2 H-pyrrolo[2,3-b]pyridin-2-one or 2,3-dihydro-[1,4]dioxane-hexenolo[2,3-b]pyridine (preferably 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, indololin-2-one or benzo[d]oxazol-2(3H)-one) bicyclic, or optionally substituted bicyclic heteroaryl, wherein the phenyl, pyridine, pyrazine, pyrimidine or pyridazine ring is fused to pyrrole, furan, thiophene, pyrazole, isoxazol, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, The pyrimidine or pyridazine ring; wherein the optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted pyrrolidine, pyrrolidone, piperidine, or morpholine. The heterocyclic, optionally substituted phenyl, or optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10-OH or -CN; preferably, R3 is -H or methyl, R4 is -H, R5 is -H, halogen, methyl or trifluoromethyl, and R2 is optionally substituted with a compound selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one or 2,3-dihydro-[1,4]dioxacyclohexeno[2,3-b]pyridine (preferably 1,3-benzodioxacyclopentene, 2,3-dihydro- 1,4-Benzadioxazine, isoindoline-1-one, indoline-2-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted with a bicyclic compound selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, benzoxazole, benzothiazole, pyrrolopyridine, pyrrolopyridine, or quinazoline (preferably indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine). A bicyclic heteroaryl group of pyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, or benzoxazole; wherein the optionally substituted bicyclic group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted... Heterocyclic compounds of pyrrolidine, pyrrolidone, piperidine, or morpholine, optionally substituted phenyl groups, or optionally substituted heteroaryl groups selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy groups; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0191] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, -CN, C1-C3 alkyl, or C1-C3 haloalkyl (preferably, R3 is -H, -CN, or C1-C3 alkyl), R4 is -H or halogen (preferably, R4 is -H), and R2 is optionally substituted with a compound selected from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoyindoline-1- A bicyclic ring of a ketone or benzo[d]oxazol-2(3H)-one, or optionally a substituted bicyclic heteroaryl ring, wherein a phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to a pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; wherein the optionally substituted bicyclic ring is optionally substituted by 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; the optionally substituted bicyclic ring The heteroaryl group is optionally substituted with 1 to 3 substituents, each of which is independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocycle selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heterocycle selected from pyrazole, isoxazole, isothiazole. The C1-C6 alkyl group is a heteroaryl group of imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR. 10 R 10R3 is -H or -CN; preferably, R4 is -H, R5 is -H, halogen, methyl, or trifluoromethyl, and R2 is a bicyclic ring optionally substituted from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, or benzo[d]oxazol-2(3H)-one, or a bicyclic heteroaryl ring optionally substituted from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, or phthalazine; wherein the optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogen, or trifluoromethyl groups. C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl is optionally substituted with -CN, -OH or C1-C3 alkoxy; wherein each optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic or heteroaryl is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0192] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, -CN, C1-C3 alkyl or C1-C3 haloalkyl (preferably, R3 is -H, -CN or C1-C3 alkyl), R4 is -H or halogen (preferably, R4 is -H), R6 is -H or halogen, and R2 is optionally substituted with a compound selected from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1, 3-Dihydro-2H-pyrrolo[2,3-b]pyridin-2-one or 2,3-dihydro-[1,4]dioxane-hexenolo[2,3-b]pyridine (preferably 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, indololin-2-one or benzo[d]oxazol-2(3H)-one) bicyclic, or optionally substituted bicyclic heteroaryl, wherein the phenyl, pyridine, pyrazine, pyrimidine or pyridazine ring is fused to pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine The alternatively substituted bicyclic ring is substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; the alternatively substituted bicyclic heteroaryl ring is substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, alternatively substituted C1-C6 alkyl, alternatively substituted C3-C5 cycloalkyl, or alternatively substituted pyrrolidine, pyrrolidone, piperidine, or... The heterocycle of morpholine, optionally substituted phenyl, or optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocycle, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10-OH or -CN; preferably, R3 is -H or methyl, R4 and R6 are each -H, and R2 is optionally substituted with a compound selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindoline-1-one, indoline-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one or 2,3-dihydro-[1,4]dioxacyclohexen[2,3-b]pyridine (preferably 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, etc.). A bicyclic ring of cyclohexene, isoindoline-1-one, indoline-2-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted with a ring selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, benzoxazole, benzothiazole, pyrrolopyrazine, or quinazoline (preferably indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole). A bicyclic heteroaryl group of azole, pyrrolopyrimidine, thiazopyridine, benzotriazole, or benzoxazole; wherein the optionally substituted bicyclic group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted pyrrolopyrimidine, or benzoxazole. The C1-C6 alkyl group is a heterocyclic compound of an alkyl group, pyrrolidone, piperidine, or morpholine, optionally substituted with a phenyl group, or optionally substituted with a heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy group; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0193] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, -CN, C1-C3 alkyl or C1-C3 haloalkyl (preferably, R3 is -H, -CN or C1-C3 alkyl), R4 is -H or halogen (preferably, R4 is -H), R6 is -H or halogen, and R2 is optionally substituted with a compound selected from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isobenzoxane, etc. A bicyclic ring of indoline-1-one or benzo[d]oxazol-2(3H)-one, or optionally a substituted bicyclic heteroaryl ring, wherein a phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to a pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; wherein the optionally substituted bicyclic ring is optionally substituted by 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; the optionally substituted bicyclic ring is substituted by 1 to 3 substituents. The bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each of which is independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocycle selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heterocycle selected from pyrazole, isoxazole, iso... Thiazole, imidazole, oxazole, or a heteroaryl group of thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10-OH or -CN; preferably, R3 is -H or methyl, R4 and R6 are each -H, and R2 is a bicyclic ring optionally substituted from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one or benzo[d]oxazol-2(3H)-one, or a bicyclic heteroaryl ring optionally substituted from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine or phthalazine; wherein the optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogen, C1-C6... The substituted C1-C6 alkyl group, C1-C6 alkoxy group, C1-C6 haloalkoxy group, optionally substituted C1-C6 alkyl group, optionally substituted C3-C5 cycloalkyl group, optionally substituted heterocyclic group selected from pyrrolidine, pyrrolidone, piperidine, or morpholine, optionally substituted phenyl group, or optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy group; wherein each optionally substituted C3-C5 cycloalkyl group, phenyl group, heterocyclic group, or heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl group, C1-C3 haloalkyl group, C1-C3 alkoxy group, C1-C3 haloalkoxy group, -NR group. 10 R 10 -OH or -CN.

[0194] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, -CN, C1-C3 alkyl or C1-C3 haloalkyl (preferably, R3 is -H, -CN or C1-C3 alkyl), R6 is -H or halogen, and R2 is optionally substituted from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3] [-b]pyridin-2-one or 2,3-dihydro-[1,4]dioxane-1-one, indolin-2-one or benzo[d]oxazol-2(3H)-one, a bicyclic ring of pyrrole, furan, thiophene, pyrazole, isoxazol-2-one or benzo[d]oxazol-2(3H)-one, or optionally a substituted bicyclic heteroaryl group, wherein the phenyl, pyridine, pyrazine, pyrimidine or pyridazine ring is fused to the pyrrole, furan, thiophene, pyrazole, isoxazol, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine or pyridazine ring. The optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic rings selected from pyrrolidine, pyrrolidone, piperidine, or morpholine. Optionally substituted phenyl groups, or optionally substituted heteroaryl groups selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy groups; wherein each optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10R3 is -H or -CN; more preferably, R5 is -H, halogen, methyl or trifluoromethyl, R6 is -H, and R2 is optionally substituted with a compound selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one or 2,3-dihydro-[1,4]dioxacyclohexen[2,3-b]pyridine (preferably 1,3-benzodioxacyclopentene, 2,3-dihydro- 1,4-Benzadioxazine, isoindoline-1-one, indoline-2-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted with a bicyclic compound selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, benzoxazole, benzothiazole, pyrrolopyridine, pyrrolopyridine, or quinazoline (preferably indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine). A bicyclic heteroaryl group of pyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, or benzoxazole; wherein the optionally substituted bicyclic group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted... Heterocyclic compounds of pyrrolidine, pyrrolidone, piperidine, or morpholine, optionally substituted phenyl groups, or optionally substituted heteroaryl groups selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy groups; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0195] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, -CN, C1-C3 alkyl, or C1-C3 haloalkyl (preferably, R3 is -H, -CN, or C1-C3 alkyl), R6 is -H or halogen, and R2 is optionally substituted with a compound selected from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, or benzo[d]oxazole. A bicyclic ring of a -2(3H)-one, or optionally a substituted bicyclic heteroaryl group, wherein a phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to a pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; wherein the optionally substituted bicyclic ring is optionally substituted by 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl group is optionally... It is substituted with 1 to 3 substituents, each of which is independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocycles selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted pyrazole, isoxazole, isothiazole, imidazole The heteroaryl group of oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10R3 is -H or -CN; more preferably, R5 is -H, halogen, methyl or trifluoromethyl, R6 is -H, and R2 is optionally substituted with a bicyclic ring selected from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindoline-1-one or benzo[d]oxazol-2(3H)-one, or optionally substituted with a bicyclic heteroaryl ring selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine or phthalazine; wherein the optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogen, methyl or trifluoromethyl groups, or trifluoromethyl groups; and R2 is optionally substituted with a bicyclic ring selected from 1,3-benzodioxane, halogen, methyl or trifluoromethyl groups, or trifluoromethyl groups. The alkyl group comprises a halogen, a C1-C6 haloalkyl group, a C1-C6 alkoxy group, a C1-C6 haloalkoxy group, a optionally substituted C1-C6 alkyl group, an optionally substituted C3-C5 cycloalkyl group, an optionally substituted heterocyclic group selected from pyrrolidine, pyrrolidone, piperidine, or morpholine, an optionally substituted phenyl group, or an optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; and each of the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is optionally substituted with 1 to 3 substituents, each of which is independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR. 10 R 10 -OH or -CN.

[0196] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R5 is -H, a halogen, a C1-C3 alkyl or a C1-C3 haloalkyl, R4 is -H or a halogen (preferably, R4 is -H), R6 is -H or a halogen, and R2 is optionally substituted with a compound selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b] A bicyclic ring of pyridin-2-one or 2,3-dihydro-[1,4]dioxane-1-one, indoline-2-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted bicyclic heteroaryl, wherein the phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to the pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; The optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic rings selected from pyrrolidine, pyrrolidone, piperidine, or morpholine. The optionally substituted phenyl group, or the optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10-OH or -CN; preferably R5 is -H, halogen, methyl or trifluoromethyl, R4 is -H, R6 is -H or halogen, and R2 is optionally substituted with a compound selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one or 2,3-dihydro-[1,4]dioxacyclohexen[2,3-b]pyridine (preferably 1,3-benzodioxacyclopentene, 2,3-dihydro-1... 4-Benzadioxane, isoindoline-1-one, indoline-2-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted with a bicyclic compound selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, benzoxazole, benzothiazole, pyrrolopyrazine, or quinazoline (preferably indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine). A bicyclic heteroaryl group of pyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, or benzoxazole; wherein the optionally substituted bicyclic group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted... Heterocyclic compounds of pyrrolidine, pyrrolidone, piperidine, or morpholine, optionally substituted phenyl groups, or optionally substituted heteroaryl groups selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy groups; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0197] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R5 is -H, halogen, C1-C3 alkyl, or C1-C3 haloalkyl, R4 is -H or halogen (preferably, R4 is -H), R6 is -H or halogen, and R2 is optionally substituted with a compound selected from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, or benzo[d]oxazol-2 ( A bicyclic ring of a 3H)-ketone, or optionally a substituted bicyclic heteroaryl ring, wherein a phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to a pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; wherein the optionally substituted bicyclic ring is optionally substituted by 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl ring is optionally substituted by 1... Up to three substituents are substituted, each substituent being independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl is optionally substituted with -CN, -OH or C1-C3 alkoxy; each optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic or heteroaryl is optionally substituted with one to three substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10R5 is -H, halogen, methyl, or trifluoromethyl; preferably, R4 is -H, R6 is -H or halogen, and R2 is a bicyclic ring optionally substituted from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, or benzo[d]oxazol-2(3H)-one, or a bicyclic heteroaryl ring optionally substituted from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, or phthalazine; wherein the optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogen, or trifluoromethyl groups. C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl is optionally substituted with -CN, -OH or C1-C3 alkoxy; wherein each optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic or heteroaryl is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0198] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, -CN, C1-C3 alkyl or C1-C3 haloalkyl (preferably, R3 is -H, -CN or C1-C3 alkyl), R4 is -H or halogen (preferably, R4 is -H), R6 is -H or halogen, and R5 is -H, halogen, C1-C3 alkyl or C1-C3 haloalkyl; preferably, R3 is -H or methyl, R4 and R6 are each -H, and R5 is -H, halogen, methyl or trifluoromethyl.

[0199] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, -CN, C1-C3 alkyl, or C1-C3 haloalkyl (preferably, R3 is -H, -CN, or C1-C3 alkyl), R4 is -H or halogen (preferably, R4 is -H), R6 is -H or halogen, R5 is -H, halogen, C1-C3 alkyl, or C1-C3 haloalkyl, and R2 is optionally substituted with a compound selected from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, indoline-2-one, etc. -one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one or 2,3-dihydro-[1,4]dioxazolene[2,3-b]pyridine (preferably 1,3-benzodioxazopenene, 2,3-dihydro-1,4-benzodioxazolene, isoindolin-1-one, indololin-2-one or benzo[d]oxazol-2(3H)-one) bicyclic, or optionally substituted bicyclic heteroaryl, wherein the phenyl, pyridine, pyrazine, pyrimidine or pyridazine ring is fused to pyrrole, furan, thiophene, pyrazole, isoxazol, Imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; wherein the optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted from pyrrolidine, pyridinium hydroxide, etc. The heterocycle of a pyrrolidone, piperidine, or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocycle, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10R3 is -OH or -CN; more preferably, R4 is -H or methyl, R6 is -H or halogen, R5 is -H, halogen, methyl or trifluoromethyl, and R2 is optionally substituted with a compound selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one or 2,3-dihydro-[1,4]dioxacyclohexen[2,3-b]pyridine (preferably 1,3-benzodioxacyclopentene, ...). 2,3-Dihydro-1,4-benzodioxane, isoindoline-1-one, indoline-2-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted with a bicyclic compound selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, benzoxazole, benzothiazole, pyrrolopyrazine, or quinazoline (preferably indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine). A bicyclic heteroaryl group of a azine, triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, or benzoxazole; wherein the optionally substituted bicyclic group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted... The substituted C1-C6 alkyl group is selected from pyrrolidine, pyrrolidone, piperidine, or morpholine; optionally substituted phenyl group; or optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy group; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0200] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, -CN, C1-C3 alkyl, or C1-C3 haloalkyl (preferably, R3 is -H, -CN, or C1-C3 alkyl), R4 is -H or halogen (preferably, R4 is -H), R6 is -H or halogen, R5 is -H, halogen, C1-C3 alkyl, or C1-C3 haloalkyl, and R2 is optionally substituted with a compound selected from 1,3-benzodioxane, The bicyclic ring of 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted bicyclic heteroaryl, wherein a phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to a pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; wherein the optionally substituted bicyclic ring is optionally substituted by 1 to 3 substituents, each substituent being independently selected from C14. 1-C6 alkyl; the optionally substituted bicyclic heteroaryl group is optionally substituted by 1 to 3 substituents, each substituent being independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic group selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heterocyclic group selected from pyrrolidine. The heteroaryl group of azole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10R3 is -H or -OH or -CN; more preferably, R4 is -H, R6 is -H or halogen, R5 is -H, halogen, methyl or trifluoromethyl, and R2 is a bicyclic ring optionally substituted from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one or benzo[d]oxazol-2(3H)-one, or a bicyclic heteroaryl ring optionally substituted from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine or phthalazine; wherein the optionally substituted bicyclic ring is optionally substituted by 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl ring is optionally substituted by 1 to 3 substituents, each substituent being independently selected from - CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl is optionally substituted with -CN, -OH or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic or heteroaryl is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0201] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R is -H.

[0202] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R7 is -CN, C1-C3 alkyl or C1-C3 haloalkyl; more preferably, R7 is -CN, methyl or trifluoromethyl.

[0203] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R8 is -H.

[0204] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R7 is -CN, C1-C3 alkyl, or C1-C3 haloalkyl, and R is -H. In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R7 is C1-C3 alkyl (preferably methyl), and R is -H.

[0205] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R8 and R are each -H.

[0206] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R7 is -CN, C1-C3 alkyl, or C1-C3 haloalkyl, and R8 is -H. In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R7 is C1-C3 alkyl (preferably methyl), and R8 is -H.

[0207] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R7 is -CN, C1-C3 alkyl, or C1-C3 haloalkyl, and R8 and R are each -H. In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R7 is C1-C3 alkyl (preferably methyl), and R8 and R are each -H.

[0208] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R7 is -CN, C1-C3 alkyl, or C1-C3 haloalkyl, R8 is -H, R is -H, and R2 is optionally substituted with a compound selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one, or 2,3-dihydro-[ [1,4]dioxane-[2,3-b]pyridine (preferably 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, indololin-2-one, or benzo[d]oxazol-2(3H)-one) bicyclic, or optionally substituted bicyclic heteroaryl, wherein the phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to the pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; wherein the optionally substituted ring is... The bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocycles selected from pyrrolidine, pyrrolidone, piperidine, or morpholine, optionally substituted... The substituted phenyl group, or optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0209] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R7 is -CN, C1-C3 alkyl, or C1-C3 haloalkyl, R8 is -H, R is -H, and R2 is optionally substituted with a bicyclic compound selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted with a bicyclic compound of the same type. A substituted bicyclic heteroaryl group, wherein a phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to a pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; wherein the optionally substituted bicyclic group is optionally substituted by 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl group is optionally substituted by 1 to 3 substituents, wherein... Each of the substituents is independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl is optionally substituted with -CN, -OH or C1-C3 alkoxy; each of the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic or heteroaryl is optionally substituted with 1 to 3 substituents, each of which is independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0210] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R7 is a C1-C3 alkyl group (preferably methyl), R8 is -H, R is -H, and R2 is optionally substituted from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one or 2,3-dihydro-[1,4]dioxane-1-[2,3-b]pyridine (preferably 1,3-benzodioxane). Bicyclic compounds of indole, 2,3-dihydro-1,4-benzodioxane, isoindoline-1-one, indoline-2-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted with a group selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, benzoxazole, benzothiazole, pyrrolopyrazine, or quinazoline (preferably indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine). A bicyclic heteroaryl group of phthalazine, triazolidine, benzimidazole, pyrrolopyrimidine, thiazopyrimidine, benzotriazole, or benzoxazole; wherein the optionally substituted bicyclic group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted... The substituted C1-C6 alkyl group is selected from pyrrolidine, pyrrolidone, piperidine, or morpholine; optionally substituted phenyl group; or optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy group; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0211] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R7 is a C1-C3 alkyl group (preferably methyl), R8 is -H, R is -H, and R2 is a bicyclic group optionally substituted from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one or benzo[d]oxazol-2(3H)-one, or a bicyclic heteroaryl group optionally substituted from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine or phthalazine; wherein the optionally substituted bicyclic group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl is optionally substituted with -CN, -OH or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic or heteroaryl is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0212] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, -CN, C1-C3 alkyl, or C1-C3 haloalkyl (preferably, R3 is -H, -CN, or C1-C3 alkyl), R7 is -CN, C1-C3 alkyl, or C1-C3 haloalkyl, and R8 and R are each -H. In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H or methyl, R7 is C1-C3 alkyl (preferably methyl), and R8 and R are each -H.

[0213] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R7 is -CN, C1-C3 alkyl, or C1-C3 haloalkyl, and R4, R8, and R are each -H. In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R7 is C1-C3 alkyl (preferably methyl), and R4, R8, and R are each -H.

[0214] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R5 is -H, a halogen, a C1-C3 alkyl or a C1-C3 haloalkyl, R7 is -CN, methyl or trifluoromethyl, and R8 and R are each -H. In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R5 is -H, a halogen, a methyl or trifluoromethyl, R7 is methyl, and R8 and R are each -H.

[0215] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, -CN, C1-C3 alkyl, or C1-C3 haloalkyl (preferably, R3 is -H, -CN, or C1-C3 alkyl), R4 is -H or halogen (preferably, R4 is -H), R6 is -H or halogen, R7 is -CN, methyl, or trifluoromethyl, R8 is -H, R is -H, and R2 is optionally substituted with a compound selected from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, indoline-2- The bicyclic ring of a ketone, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one, or 2,3-dihydro-[1,4]dioxazolene[2,3-b]pyridine (preferably 1,3-benzodioxazopenene, 2,3-dihydro-1,4-benzodioxazopenene, isoindolin-1-one, indololin-2-one, or benzo[d]oxazol-2(3H)-one), or optionally a substituted bicyclic heteroaryl group, wherein the phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to pyrrole, furan, thiophene, pyrazole, isoxazol, imidazole, or imidazole ring. The ring may contain azoles, oxazoles, thiazoles, triazoles, pyridines, pyrazines, pyrimidines, or pyridazines; wherein the optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl groups, C1-C6 alkoxy groups, C1-C6 haloalkoxy groups, optionally substituted C1-C6 alkyl groups, optionally substituted C3-C5 cycloalkyl groups, optionally substituted groups selected from pyrrolidines, pyrazines, etc. The heterocycle of a pyrrolidone, piperidine, or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocycle, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10-OH or -CN; preferably, R3 is -H or methyl, R4 is -H, R6 is -H or halogen, R5 is -H, halogen, methyl or trifluoromethyl, R7 is methyl, R8 is -H, R is -H, and R2 is optionally substituted with a compound selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one or 2,3-dihydro-[1,4]dioxacyclohexeno[2,3-b]pyridine (preferably 1... 3-Benzadioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindoline-1-one, indoline-2-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted with a bicyclic compound selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, benzoxazole, benzothiazole, pyrrolopyrazine, or quinazoline (preferably indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine). The bicyclic heteroaryl group of (imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, or benzoxazole); wherein the optionally substituted bicyclic group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, any The optionally substituted C1-C6 alkyl group is selected from pyrrolidine, pyrrolidone, piperidine, or morpholine; the optionally substituted phenyl group is selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; and each of the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is optionally substituted with 1 to 3 substituents, each of which is independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, or -NR. 10 R 10 -OH or -CN.

[0216] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, -CN, C1-C3 alkyl, or C1-C3 haloalkyl (preferably, R3 is -H, -CN, or C1-C3 alkyl), R4 is -H or halogen (preferably, R4 is -H), R6 is -H or halogen, R7 is -CN, methyl, or trifluoromethyl, R8 is -H, R is -H, and R2 is optionally substituted with a compound selected from 1,3-benzodioxane, 2 3-Dihydro-1,4-benzodioxane, isoindolin-1-one, or benzo[d]oxazol-2(3H)-one bicyclic, or optionally substituted bicyclic heteroaryl, wherein a phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to a pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; wherein the optionally substituted bicyclic ring is optionally substituted by 1 to 3 substituents, each substituent being independently selected from C1. -C6 alkyl; the optionally substituted bicyclic heteroaryl group is optionally substituted by 1 to 3 substituents, each substituent being independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocycle selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heterocycle selected from pyrrolidine. The heteroaryl group of azole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10-OH or -CN; preferably, R3 is -H or methyl, R4 is -H, R6 is -H or halogen, R5 is -H, halogen, methyl or trifluoromethyl, R7 is methyl, R8 is -H, R is -H, and R2 is optionally substituted with a di(3H)-selected from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one or benzo[d]oxazol-2(3H)-one. The ring, or optionally substituted, is a bicyclic heteroaryl group selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, or phthalazine; wherein the optionally substituted bicyclic ring is optionally substituted by 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl group is optionally substituted by 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups. Each of the following is independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl is optionally substituted with -CN, -OH or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic or heteroaryl is each optionally substituted with 1 to 3 substituents, each of which is independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0217] In yet another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, each R9 is independently -H, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C3-C5 cycloalkyl. In yet another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, each R9 is independently -H, halogen, C1-C3 alkyl, or C1-C3 haloalkyl; preferably, each R9 is independently -H, halogen, methyl, or trifluoromethyl.

[0218] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0219]

[0220] Each R9 is independently -H, halogen, -CN, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, or C3-C5 cycloalkyl; preferably, each R9 is independently -H, halogen, -CN, methyl, trifluoromethyl, methoxy, or cyclopropyl.

[0221] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0222]

[0223] Each R9 is independently -H, halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, or C3-C5 cycloalkyl; preferably, each R9 is independently -H, halogen, methyl, trifluoromethyl, methoxy, or cyclopropyl.

[0224] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0225]

[0226] Preferably, each R9 is independently -H, halogen, C1-C3 alkyl, C1-C3 haloalkyl, or C3-C5 cycloalkyl. More preferably, each R9 is independently -H, halogen, methyl, trifluoromethyl, or cyclopropyl.

[0227] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0228] Preferably, each R9 is independently -H, halogen, C1-C3 alkyl, or C1-C3 haloalkyl. More preferably, each R9 is independently -H, halogen, methyl, or trifluoromethyl.

[0229] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0230]

[0231] Each R9 is independently -H, halogen, -CN, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C3-C5 cycloalkyl; preferably, each R9 is independently -H, halogen, -CN, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, or C3-C5 cycloalkyl; more preferably, each R9 is independently -H, halogen, -CN, methyl, trifluoromethyl, methoxy, or cyclopropyl.

[0232] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0233]

[0234] Each R9 is independently -H, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C3-C5 cycloalkyl; preferably, each R9 is independently -H, halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, or C3-C5 cycloalkyl; more preferably, each R9 is independently -H, halogen, methyl, trifluoromethyl, methoxy, or cyclopropyl.

[0235] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0236] Each R9 is independently -H, halogen, -CN, C1-C3 alkyl, C1-C3 haloalkyl, or C1-C3 alkoxy. Preferably, each R9 is independently -H, halogen, C1-C3 alkyl, or C1-C3 haloalkyl. More preferably, each R9 is independently -H, halogen, methyl, or trifluoromethyl.

[0237] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0238] R9 is -H, halogen, -CN, C1-C3 haloalkyl, or C1-C3 alkoxy. Preferably, R9 is -H, halogen, or C1-C3 haloalkyl. More preferably, R9 is -H or trifluoromethyl.

[0239] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0240] R9 is -H, halogen, -CN, C1-C3 haloalkyl, or C1-C3 alkoxy. Preferably, R9 is -H, halogen, or C1-C3 haloalkyl. More preferably, R9 is -H or halogen. Even more preferably, R9 is -H or fluorine.

[0241] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0242] R9 is -H, halogen, -CN, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, or C3-C5 cycloalkyl. Preferably, R9 is -H, halogen, C1-C3 alkyl, C1-C3 haloalkyl, or C3-C5 cycloalkyl. More preferably, R9 is -H, halogen, methyl, trifluoromethyl, or cyclopropyl.

[0243] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0244] R9 is -H, a halogen, or a C1-C3 haloalkyl group. Preferably, R9 is a halogen or a trifluoromethyl group. More preferably, R9 is chlorine or a trifluoromethyl group.

[0245] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0246] R9 is -H, halogen, -CN, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkoxy. Preferably, R9 is -H, halogen, C1-C6 alkyl, or C1-C6 haloalkyl. More preferably, R9 is -H, halogen, C1-C3 alkyl, or C1-C3 haloalkyl.

[0247] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0248] R9 is -H, halogen, -CN, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, or C3-C5 cycloalkyl. Preferably, R9 is -H, halogen, C1-C3 alkyl, C1-C3 haloalkyl, or C3-C5 cycloalkyl. More preferably, R9 is -H, halogen, methyl, trifluoromethyl, or cyclopropyl.

[0249] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0250]

[0251] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0252]

[0253] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0254]

[0255]

[0256] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, -CN, C1-C3 alkyl, or C1-C3 haloalkyl, R4 is -H or halogen, R6 is -H or halogen, R5 is -H, halogen, C1-C3 alkyl, or C1-C3 haloalkyl, and R1 is a group of the following formula:

[0257]

[0258] Each R9 is independently -H, halogen, C1-C3 alkyl, C1-C3 haloalkyl, or C3-C5 cycloalkyl. Preferably, R3 is -H, methyl, or trifluoromethyl, R4 is -H or halogen, R6 is -H or halogen, R5 is -H, halogen, methyl, or trifluoromethyl, and each R9 is independently -H, halogen, methyl, trifluoromethyl, or cyclopropyl.

[0259] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, -CN, or C1-C3 alkyl, R4 is -H, R6 is -H or halogen, R5 is -H, halogen, C1-C3 alkyl, or C1-C3 haloalkyl, and R1 is a group of the following formula:

[0260] Each R9 is independently -H, halogen, C1-C3 alkyl, or C1-C3 haloalkyl. Preferably, R3 is -H or methyl, R4 is -H, R6 is -H or halogen, R5 is -H, halogen, methyl, or trifluoromethyl, and each R9 is independently -H, halogen, methyl, or trifluoromethyl.

[0261] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R7 is -CN, methyl, or trifluoromethyl, R8 and R are each -H, and R1 is a group of the following formula:

[0262]

[0263] Each R9 is independently -H, halogen, C1-C3 alkyl, C1-C3 haloalkyl or C3-C5 cycloalkyl; more preferably, R7 is methyl, R8 and R are each -H, and each R9 is independently -H, halogen, methyl, trifluoromethyl or cyclopropyl.

[0264] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R7 is -CN, methyl, or trifluoromethyl, R8 and R are each -H, and R1 is a group of the following formula:

[0265] Each R9 is independently -H, halogen, C1-C3 alkyl or C1-C3 haloalkyl; more preferably, R7 is methyl, R8 and R are each -H, and each R9 is independently -H, halogen, methyl or trifluoromethyl.

[0266] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, -CN, C1-C3 alkyl, or C1-C3 haloalkyl, R4 is -H or halogen, R8 and R are each -H, R5 is -H, halogen, C1-C3 alkyl, or C1-C3 haloalkyl, R6 is -H or halogen, R7 is -CN, methyl, or trifluoromethyl, and R1 is a group of the following formula:

[0267]

[0268] Each R9 is independently -H, halogen, C1-C3 alkyl, C1-C3 haloalkyl, or C3-C5 cycloalkyl; more preferably, R3 is -H, methyl, or trifluoromethyl, R4 is -H or halogen, R6 is -H or halogen, R8 and R are each -H, R5 is -H, halogen, methyl, or trifluoromethyl, R7 is methyl, and each R9 is independently -H, halogen, methyl, trifluoromethyl, or cyclopropyl.

[0269] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, -CN, or C1-C3 alkyl, R4, R8, and R are each -H, R5 is -H, halogen, C1-C3 alkyl, or C1-C3 haloalkyl, R6 is -H or halogen, R7 is -CN, methyl, or trifluoromethyl, and R1 is a group of the following formula:

[0270] Each R9 is independently -H, halogen, C1-C3 alkyl, or C1-C3 haloalkyl; more preferably, R3 is -H or methyl, R4, R6, R8, and R are each -H, R5 is -H, halogen, methyl, or trifluoromethyl, R7 is methyl, and each R9 is independently -H, halogen, methyl, or trifluoromethyl.

[0271] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, -CN, C1-C3 alkyl, or C1-C3 haloalkyl, R4 is -H or halogen, R8 and R are each -H, R5 is -H, halogen, C1-C3 alkyl, or C1-C3 haloalkyl, R6 is -H or halogen, R7 is -CN, methyl, or trifluoromethyl, and R1 is a group of the following formula:

[0272] Each R9 is independently -H, halogen, C1-C3 alkyl, or C1-C3 haloalkyl; preferably, R3 is -H, methyl, or trifluoromethyl, R4 is -H or halogen, R6 is -H or halogen, R8 and R are each -H, R5 is -H, halogen, methyl, or trifluoromethyl, R7 is methyl, and each R9 is independently -H, halogen, methyl, or trifluoromethyl.

[0273] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, -CN, or C1-C3 alkyl, R4, R8, and R are each -H, R5 is -H, halogen, C1-C3 alkyl, or C1-C3 haloalkyl, R6 is -H or halogen, R7 is -CN, methyl, or trifluoromethyl, and R1 is a group of the following formula:

[0274] Wherein R9 is -H, halogen, or C1-C3 haloalkyl; preferably, R3 is -H or methyl, R4, R6, R8, and R are each -H, R5 is -H, halogen, methyl, or trifluoromethyl, R7 is methyl, and R9 is -H or trifluoromethyl.

[0275] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, -CN, or C1-C3 alkyl, R4, R8, and R are each -H, R5 is -H, halogen, C1-C3 alkyl, or C1-C3 haloalkyl, R6 is -H or halogen, R7 is -CN, methyl, or trifluoromethyl, and R1 is a group of the following formula:

[0276] Wherein R9 is -H, halogen, or C1-C3 haloalkyl; preferably, R3 is -H or methyl, R4, R6, R8, and R are each -H, R5 is -H, halogen, methyl, or trifluoromethyl, R7 is methyl, and R9 is -H or halogen.

[0277] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, -CN, C1-C3 alkyl, or C1-C3 haloalkyl, R4 is -H or halogen, R8 and R are each -H, R5 is -H, halogen, C1-C3 alkyl, or C1-C3 haloalkyl, R6 is -H or halogen, R7 is -CN, methyl, or trifluoromethyl, and R1 is a group of the following formula:

[0278] Wherein R9 is -H, halogen, C1-C3 alkyl, C1-C3 haloalkyl or C3-C5 cycloalkyl; preferably, R3 is -H, methyl or trifluoromethyl, R4 is -H or halogen, R6 is -H or halogen, R8 and R are each -H, R5 is -H, halogen, methyl or trifluoromethyl, R7 is methyl, and R9 is -H, halogen, methyl, trifluoromethyl or cyclopropyl.

[0279] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, -CN, or C1-C3 alkyl, R4, R8, and R are each -H, R5 is -H, halogen, C1-C3 alkyl, or C1-C3 haloalkyl, R6 is -H or halogen, R7 is -CN, methyl, or trifluoromethyl, and R1 is a group of the following formula:

[0280] Wherein R9 is -H, halogen, or C1-C3 haloalkyl; preferably, R3 is -H or methyl, R4, R6, R8, and R are each -H, R5 is -H, halogen, methyl, or trifluoromethyl, R7 is methyl, and R9 is independently halogen or trifluoromethyl.

[0281] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, -CN, or C1-C3 alkyl, R4, R8, and R are each -H, R5 is -H, halogen, C1-C3 alkyl, or C1-C3 haloalkyl, R6 is -H or halogen, R7 is -CN, methyl, or trifluoromethyl, and R1 is a group of the following formula:

[0282] Wherein R9 is -H, halogen, C1-C3 alkyl or C1-C3 haloalkyl; preferably, R3 is -H or methyl, R4, R6, R8 and R are each -H, R5 is -H, halogen, methyl or trifluoromethyl, R7 is methyl, and R9 is -H, halogen, C1-C3 alkyl or C1-C3 haloalkyl.

[0283] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R3 is -H, -CN, C1-C3 alkyl, or C1-C3 haloalkyl, R4 is -H or halogen, R8 and R are each -H, R5 is -H, halogen, C1-C3 alkyl, or C1-C3 haloalkyl, R6 is -H or halogen, R7 is -CN, methyl, or trifluoromethyl, and R1 is a group of the following formula:

[0284] Wherein R9 is -H, halogen, C1-C3 alkyl, C1-C3 haloalkyl or C3-C5 cycloalkyl; preferably, R3 is -H, methyl or trifluoromethyl, R4 is -H or halogen, R6 is -H or halogen, R8 and R are each -H, R5 is -H, halogen, methyl or trifluoromethyl, R7 is methyl, and R9 is -H, halogen, methyl, trifluoromethyl or cyclopropyl.

[0285] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0286]

[0287] Each R9 is independently -H, halogen, C1-C3 alkyl, C1-C3 haloalkyl, or C3-C5 cycloalkyl; and R2 is optionally substituted with a compound selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one, or 2,3-dihydro-[1,4]dioxacyclohexen[2,3-] b] A bicyclic ring of pyridine (preferably 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, indololin-2-one, or benzo[d]oxazol-2(3H)-one), or optionally a substituted bicyclic heteroaryl ring, wherein the phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to a pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; wherein the optionally substituted bicyclic ring is optionally substituted with 1 to 3 determinate rings. The alternatively substituted bicyclic heteroaryl group is optionally substituted by 1 to 3 substituents, each of which is independently selected from halogens and C1-C6 alkyl groups; the alternatively substituted bicyclic heteroaryl group is optionally substituted by 1 to 3 substituents, each of which is independently selected from -CN, halogens, C1-C6 haloalkyl groups, C1-C6 alkoxy groups, C1-C6 haloalkoxy groups, optionally substituted C1-C6 alkyl groups, optionally substituted C3-C5 cycloalkyl groups, optionally substituted heterocycles selected from pyrrolidine, pyrrolidone, piperidine, or morpholine, optionally substituted phenyl groups, etc. Alternatively, a heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole may be substituted; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN. Preferably, each R9 is independently -H, halogen, C1-C3 alkyl, or C1-C3 haloalkyl. Most preferably, each R9 is independently -H, halogen, methyl, or trifluoromethyl.

[0288] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0289] R2 is a bicyclic ring optionally substituted from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, or benzo[d]oxazol-2(3H)-one, or a bicyclic heteroaryl ring optionally substituted, wherein the phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to a pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; wherein the optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C 6-alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl is optionally substituted with -CN, -OH or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic or heteroaryl is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN. Preferably, each R9 is independently -H, halogen, C1-C3 alkyl, or C1-C3 haloalkyl. Most preferably, each R9 is independently -H, halogen, methyl, or trifluoromethyl.

[0290] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0291] Each R9 is independently -H, halogen, C1-C3 alkyl, or C1-C3 haloalkyl, and R2 is optionally substituted with a compound selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindoline-1-one, indoline-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one, or 2,3-dihydro-[1,4]dioxacyclohexen[2,3-b]pyridine (preferably 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, etc.). A bicyclic ring of cyclohexene, isoindoline-1-one, indoline-2-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted with a ring selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, benzoxazole, benzothiazole, pyrrolopyrazine, or quinazoline (preferably indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole). A bicyclic heteroaryl group of azole, pyrrolopyrimidine, thiazopyridine, benzotriazole, or benzoxazole; wherein the optionally substituted bicyclic group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted pyrrolopyrimidine, or benzoxazole. The C1-C6 alkyl group is a heterocyclic compound of an alkyl group, pyrrolidone, piperidine, or morpholine, optionally substituted with a phenyl group, or optionally substituted with a heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy group; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN. Preferably, R9 is independently -H, halogen, methyl or trifluoromethyl.

[0292] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0293] Wherein R9 is -H, halogen, or C1-C3 haloalkyl, and R2 is optionally substituted with a compound selected from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindoline-1-one, indoline-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one, or 2,3-dihydro-[1,4]dioxane-1-[2,3-b]pyridine (preferably 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindoline-1-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridine). A bicyclic ring of 1-one, indoline-2-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted with a ring selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, benzoxazole, benzothiazole, pyrrolopyrazine, or quinazoline (preferably indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyridine). A bicyclic heteroaryl group of pyrimidine, thiazopyridine, benzotriazole, or benzoxazole; wherein the optionally substituted bicyclic group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted pyrrolidine, pyrrole... The heterocycle of an alkyl ketone, piperidine, or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocycle, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN. Preferably, R9 is -H or trifluoromethyl.

[0294] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0295] Wherein R9 is -H, halogen, or C1-C3 haloalkyl, and R2 is a bicyclic ring optionally substituted from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, or benzo[d]oxazol-2(3H)-one, or a bicyclic heteroaryl ring optionally substituted from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, or phthalazine; wherein the optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl; wherein the optionally substituted bicyclic heteroaryl ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogen, C1-C6 haloalkyl, C 1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl is optionally substituted with -CN, -OH or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic or heteroaryl is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN. Preferably, R9 is -H or trifluoromethyl.

[0296] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0297] Wherein R9 is -H, halogen, or C1-C3 haloalkyl, and R2 is optionally substituted with a compound selected from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindoline-1-one, indoline-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one, or 2,3-dihydro-[1,4]dioxane-1-[2,3-b]pyridine (preferably 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindoline-1-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridine). A bicyclic ring of 1-one, indoline-2-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted with a ring selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, benzoxazole, benzothiazole, pyrrolopyrazine, or quinazoline (preferably indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyridine). A bicyclic heteroaryl group of pyrimidine, thiazopyridine, benzotriazole, or benzoxazole; wherein the optionally substituted bicyclic group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted pyrrolidine, pyrrole... The heterocycle of an alkyl ketone, piperidine, or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocycle, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN. Preferably, R9 is -H or a halogen.

[0298] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0299] Wherein R9 is -H, halogen, C1-C3 alkyl, C1-C3 haloalkyl, or C3-C5 cycloalkyl, and R2 is optionally substituted with a compound selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindoline-1-one, indoline-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one, or 2,3-dihydro-[1,4]dioxacyclohexen[2,3-b]pyridine (preferably 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene). The bicyclic ring of dioxane, isoindoline-1-one, indoline-2-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted with a ring selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, or triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, benzoxazole, benzothiazole, pyrrolopyridine, or quinazoline (preferably indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine) The bicyclic heteroaryl group of benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, or benzoxazole; wherein the optionally substituted bicyclic group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted from pyrrolopyrimidine, etc. The heterocyclic compound of pyrrolidone, piperidine, or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN; preferably, R9 is -H, halogen, methyl, trifluoromethyl or cyclopropyl.

[0300] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0301] R9 is a halogen or a C1-C3 haloalkyl group, and R2 is a bicyclic ring optionally substituted from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, or benzo[d]oxazol-2(3H)-one, or a bicyclic heteroaryl group optionally substituted from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, or phthalazine; wherein the optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogen, C1-C6 haloalkyl, C1 -C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl is optionally substituted with -CN, -OH or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic or heteroaryl is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN; preferably, R9 is a halogen or trifluoromethyl. More preferably, R9 is chlorine or trifluoromethyl.

[0302] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0303] Wherein R9 is -H, halogen, C1-C3 alkyl, or C1-C3 haloalkyl, and R2 is optionally substituted with a material selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindoline-1-one, indoline-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one, or 2,3-dihydro-[1,4]dioxacyclohexen[2,3-b]pyridine (preferably 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene). The bicyclic ring of isoindoline-1-one, indoline-2-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted with a ring selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, benzoxazole, benzothiazole, pyrrolopyrazine, or quinazoline (preferably indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole) The bicyclic heteroaryl group of pyrrolopyrimidine, thiazopyridine, benzotriazole, or benzoxazole; wherein the optionally substituted bicyclic group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted alkyl group selected from pyrroloidine, etc. The heterocycle of pyrrolidone, piperidine, or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocycle, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0304] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0305] R9 is -H, halogen, C1-C3 alkyl, or C1-C3 haloalkyl, and R2 is a bicyclic ring optionally substituted from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, or benzo[d]oxazol-2(3H)-one, or a bicyclic heteroaryl ring optionally substituted from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, or phthalazine; wherein the optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl; the optionally substituted bicyclic heteroaryl ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogen, or C1-C6 haloalkyl. Alkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl is optionally substituted with -CN, -OH or C1-C3 alkoxy; wherein each optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic or heteroaryl is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN.

[0306] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0307] Wherein R9 is -H, halogen, C1-C3 alkyl, C1-C3 haloalkyl, or C3-C5 cycloalkyl, and R2 is optionally substituted with a compound selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindoline-1-one, indoline-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one, or 2,3-dihydro-[1,4]dioxacyclohexen[2,3-b]pyridine (preferably 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, etc.). Dioxane, isoindoline-1-one, indoline-2-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted with a bicyclic compound selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, benzoxazole, benzothiazole, pyrrolopyridine, or quinazoline (preferably indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, benzo[d]oxazine, benzo[d] ... A bicyclic heteroaryl group of imidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, or benzoxazole; wherein the optionally substituted bicyclic group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted from pyrrolopyrimidine, etc. The heterocyclic compound of pyrrolidone, piperidine, or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 -OH or -CN; preferably, R9 is -H, halogen, methyl, trifluoromethyl or cyclopropyl.

[0308] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R2 is optionally substituted from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one or 2,3-dihydro-[1,4]dioxacyclohexen[2,3-b]pyridine (preferably 1,3- A bicyclic ring of benzo[d]oxazol-2(3H)-one, or optionally substituted bicyclic heteroaryl, wherein a phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to a pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; wherein the optionally substituted bicyclic ring is optionally substituted by 1 to 3 substituents. Each of the substituents is independently selected from C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl group is optionally substituted by 1 to 3 substituents, each of which is independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocycle selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted... The substituted heteroaryl group is selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR. 10 R 10 R3 is -H, -CN, C1-C3 alkyl, or C1-C3 haloalkyl, R4 is -H or halogen, R6 is -H or halogen, R5 is -H, halogen, C1-C3 alkyl, or C1-C3 haloalkyl, and R1 is a group of the following formula:

[0309]

[0310] Each R9 is independently -H, halogen, C1-C3 alkyl, C1-C3 haloalkyl, or C3-C5 cycloalkyl. Preferably, R3 is -H, methyl, or trifluoromethyl, R4 is -H or halogen, R6 is -H or halogen, R5 is -H, halogen, methyl, or trifluoromethyl, and each R9 is independently -H, halogen, methyl, trifluoromethyl, or cyclopropyl.

[0311] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R2 is a optionally substituted bicyclic ring selected from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, or benzo[d]oxazol-2(3H)-one, or an optionally substituted bicyclic heteroaryl ring, wherein a phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to a pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; wherein the optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl is optionally substituted with -CN, -OH or C1-C3 alkoxy; wherein each optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic or heteroaryl is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 R3 is -H, -CN, or a C1-C3 alkyl group; R4 is -H; R6 is -H or a halogen; R5 is -H, a halogen, a C1-C3 alkyl group, or a C1-C3 haloalkyl group; and R1 is a group of the following formula:

[0312] Each R9 is independently -H, halogen, or C1-C3 haloalkyl. Preferably, R3 is -H or methyl, R4 and R6 are each -H, R5 is -H, halogen, methyl, or trifluoromethyl, and each R9 is independently -H, halogen, methyl, or trifluoromethyl.

[0313] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R2 is optionally substituted from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one or 2,3-dihydro-[1,4]dioxacyclohexen[2,3-b]pyridine (preferably 1,3- A bicyclic ring of benzo[d]oxazol-2(3H)-one, or optionally substituted bicyclic heteroaryl, wherein a phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to a pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; wherein the optionally substituted bicyclic ring is optionally substituted by 1 to 3 substituents. Each of the substituents is independently selected from C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl group is optionally substituted by 1 to 3 substituents, each of which is independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocycle selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted... The substituted heteroaryl group is selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR. 10 R 10 R7 is -CN, methyl, or trifluoromethyl, R8 and R are each -H, and R1 is a group of the following formula:

[0314]

[0315] Each R9 is independently -H, halogen, methyl, C1-C3 haloalkyl, or cyclopropyl.

[0316] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R2 is a optionally substituted bicyclic ring selected from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, or benzo[d]oxazol-2(3H)-one, or an optionally substituted bicyclic heteroaryl ring, wherein a phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to a pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; wherein the optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl is optionally substituted with -CN, -OH or C1-C3 alkoxy; wherein each optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic or heteroaryl is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 R7 is -CN, methyl, or trifluoromethyl, R8 and R are each -H, and R1 is a group of the following formula:

[0317] Each R9 is independently -H, halogen, methyl, or C1-C3 haloalkyl.

[0318] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0319] Each R9 is independently -H, halogen, methyl, or trifluoromethyl, and R2 is optionally substituted with a compound selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, indolin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one, or 2,3-dihydro-[1,4]dioxacyclohexen[2,3-b]pyridine (preferably 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridine). A bicyclic ring of 1-line-one, indoline-2-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted with a ring selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, benzoxazole, benzothiazole, pyrrolopyrazine, or quinazoline (preferably indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyridine). A bicyclic heteroaryl group of pyrimidine, thiazopyridine, benzotriazole, or benzoxazole; wherein the optionally substituted bicyclic group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted pyrrolidine, pyridine... The heterocycle of a pyrrolidone, piperidine, or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocycle, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 R7 is a C1-C3 alkyl group (preferably methyl), and R8 and R are each -H.

[0320] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0321] R9 is -H, halogen, or trifluoromethyl (preferably, R9 is -H or trifluoromethyl), and R2 is optionally substituted with a compound selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one, or 2,3-dihydro-[1,4]dioxacyclohexen[2,3-b]pyridine (preferably 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, etc.). A bicyclic compound of hexene, isoindoline-1-one, indoline-2-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted with a compound selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, benzoxazole, benzothiazole, pyrrolopyrazine, or quinazoline (preferably indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole). A bicyclic heteroaryl group of azole, pyrrolopyrimidine, thiazopyridine, benzotriazole, or benzoxazole; wherein the optionally substituted bicyclic group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted pyrroloalkyl. The C1-C6 alkyl group is a heterocyclic compound of pyrrolidone, piperidine, or morpholine, optionally substituted with a phenyl group, or optionally substituted with a heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR. 10 R 10 R7 is a C1-C3 alkyl group (preferably methyl), and R8 and R are each -H.

[0322] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0323] R9 is -H, a halogen, or a trifluoromethyl group (preferably, R9 is -H or a trifluoromethyl group), and R2 is a bicyclic ring optionally substituted from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted from a bicyclic heteroaryl group selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, or phthalazine; wherein the optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, a halogen, or a C1-C6 alkyl group. The C1-C6 alkyl group, C1-C6 alkoxy group, C1-C6 haloalkoxy group, optionally substituted C1-C6 alkyl group, optionally substituted C3-C5 cycloalkyl group, optionally substituted heterocyclic group selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl group, or optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH or C1-C3 alkoxy group; wherein the optionally substituted C3-C5 cycloalkyl group, phenyl group, heterocyclic group or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl group, C1-C3 haloalkyl group, C1-C3 alkoxy group, C1-C3 haloalkoxy group, -NR group. 10 R 10 R7 is a C1-C3 alkyl group (preferably methyl), and R8 and R are each -H.

[0324] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0325] R9 is -H, a halogen, or a trifluoromethyl group (preferably, R9 is -H or a halogen), and R2 is optionally substituted with a group selected from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one, or 2,3-dihydro-[1,4]dioxane-[2,3-b]pyridine (preferably 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane). The bicyclic ring of isoindoline-1-one, indoline-2-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted with a ring selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, benzoxazole, benzothiazole, pyrrolopyrazine, or quinazoline (preferably indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole) The bicyclic heteroaryl group of pyrrolopyrimidine, thiazopyridine, benzotriazole, or benzoxazole; wherein the optionally substituted bicyclic group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted alkyl group selected from pyrroloidine, etc. The heterocycle of pyrrolidone, piperidine, or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocycle, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 R7 is a C1-C3 alkyl group (preferably methyl), and R8 and R are each -H.

[0326] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0327] Wherein R9 is -H, halogen, methyl, trifluoromethyl, or cyclopropyl, and R2 is optionally substituted with a compound selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindoline-1-one, indoline-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one, or 2,3-dihydro-[1,4]dioxacyclohexen[2,3-b]pyridine (preferably 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindoline). A bicyclic ring of indole-1-one, indololin-2-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted with a ring selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, benzoxazole, benzothiazole, pyrrolopyrazine, or quinazoline (preferably indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyridine). A bicyclic heteroaryl group of pyrimidine, thiazopyridine, benzotriazole, or benzoxazole; wherein the optionally substituted bicyclic group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted pyrrolidine, pyridine... The heterocycle of a pyrrolidone, piperidine, or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocycle, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 R7 is a C1-C3 alkyl group (preferably methyl), and R8 and R are each -H.

[0328] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0329] R9 is -H, a halogen, or a trifluoromethyl group (preferably, R9 is a halogen or a trifluoromethyl group), and R2 is a bicyclic ring optionally substituted from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindoline-1-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted from a bicyclic heteroaryl group selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, or phthalazine; wherein the optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, a halogen, or a C1-C6 alkyl group. The C1-C6 alkyl group, C1-C6 alkoxy group, C1-C6 haloalkoxy group, optionally substituted C1-C6 alkyl group, optionally substituted C3-C5 cycloalkyl group, optionally substituted heterocyclic group selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl group, or optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH or C1-C3 alkoxy group; wherein the optionally substituted C3-C5 cycloalkyl group, phenyl group, heterocyclic group or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl group, C1-C3 haloalkyl group, C1-C3 alkoxy group, C1-C3 haloalkoxy group, -NR group. 10 R 10 R7 is a C1-C3 alkyl group (preferably methyl), and R8 and R are each -H.

[0330] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0331] Wherein R9 is -H, halogen, C1-C3 alkyl, or C1-C3 haloalkyl, and R2 is optionally substituted from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one, or 2,3-dihydro-[1,4]dioxacyclohexen[2,3-b]pyridine (preferably 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, ... A bicyclic ring of isoindoline-1-one, indoline-2-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted with a ring selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, benzoxazole, benzothiazole, pyrrolopyrazine, or quinazoline (preferably indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrazolopyridine). A bicyclic heteroaryl group of pyrrolidine, thiazopyridine, benzotriazole, or benzoxazole; wherein the optionally substituted bicyclic group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted pyrrolidine. The C1-C6 alkyl group is a heterocyclic compound of pyrrolidone, piperidine, or morpholine, optionally substituted with a phenyl group, or optionally substituted with a heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR. 10 R 10 R7 is a C1-C3 alkyl group (preferably methyl), and R8 and R are each -H.

[0332] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0333] Wherein R9 is -H, halogen, C1-C3 alkyl, or C1-C3 haloalkyl, and R2 is a bicyclic ring optionally substituted from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, or benzo[d]oxazol-2(3H)-one, or a bicyclic heteroaryl ring optionally substituted from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, or phthalazine; wherein the optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl; the optionally substituted bicyclic heteroaryl ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogen, or C1-C6 haloalkyl. Alkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl is optionally substituted with -CN, -OH or C1-C3 alkoxy; wherein each optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic or heteroaryl is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 R7 is a C1-C3 alkyl group (preferably methyl), and R8 and R are each -H.

[0334] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0335] Wherein R9 is -H, halogen, methyl, trifluoromethyl, or cyclopropyl, and R2 is optionally substituted from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindoline-1-one, indoline-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one, or 2,3-dihydro-[1,4]dioxane-[2,3-b]pyridine (preferably 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindoline-2-one, etc.). A bicyclic ring of 1-one, indoline-2-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted with a ring selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, benzoxazole, benzothiazole, pyrrolopyrazine, or quinazoline (preferably indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyrimidine). A bicyclic heteroaryl group of pyridine, thiazopyridine, benzotriazole, or benzoxazole; wherein the optionally substituted bicyclic group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted pyrrolidine, pyr ... The heterocycle of a pyrrolidone, piperidine, or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocycle, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 R7 is a C1-C3 alkyl group (preferably methyl), and R8 and R are each -H.

[0336] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R2 is optionally substituted from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one or 2,3-dihydro-[1,4]dioxacyclohexen[2,3-b]pyridine (preferably 1,3- A bicyclic ring of benzo[d]oxazol-2(3H)-one, or optionally substituted bicyclic heteroaryl, wherein a phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to a pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; wherein the optionally substituted bicyclic ring is optionally substituted by 1 to 3 substituents. Each of the substituents is independently selected from C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl group is optionally substituted by 1 to 3 substituents, each of which is independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocycle selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted... The substituted heteroaryl group is selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR. 10 R 10 R3 is -H, -CN, C1-C3 alkyl, or C1-C3 haloalkyl; R4 is -H or halogen; R8 and R are each -H; R5 is -H, halogen, C1-C3 alkyl, or C1-C3 haloalkyl; R6 is -H or halogen; R7 is -CN, methyl, or trifluoromethyl; and R1 is a group of the following formula:

[0337]

[0338] Each R9 is independently -H, halogen, methyl, C1-C3 haloalkyl, or cyclopropyl.

[0339] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R2 is a optionally substituted bicyclic ring selected from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, or benzo[d]oxazol-2(3H)-one, or an optionally substituted bicyclic heteroaryl ring, wherein a phenyl, pyridine, pyrazine, pyrimidine, or pyridazine ring is fused to a pyrrole, furan, thiophene, pyrazole, isoxazole, imidazole, oxazole, thiazole, triazole, pyridine, pyrazine, pyrimidine, or pyridazine ring; wherein the optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogen, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted heterocyclic selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl is optionally substituted with -CN, -OH or C1-C3 alkoxy; wherein each optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic or heteroaryl is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 R3 is -H, -CN, or C1-C3 alkyl; R4, R8, and R are each -H; R5 is -H, halogen, C1-C3 alkyl, or C1-C3 haloalkyl; R6 is -H or halogen; R7 is -CN, methyl, or trifluoromethyl; and R1 is a group of the following formula:

[0340] Each R9 is independently -H, halogen, methyl, or C1-C3 haloalkyl.

[0341] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0342] Each R9 is independently -H, halogen, methyl, or trifluoromethyl, and R2 is optionally substituted with a compound selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindoline-1-one, indoline-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one, or 2,3-dihydro-[1,4]dioxacyclohexen[2,3-b]pyridine (preferably 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindoline). A bicyclic ring of indole-1-one, indololin-2-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted with a ring selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, or triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, benzoxazole, benzothiazole, pyrrolopyrazine, or quinazoline (preferably indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyridine). A bicyclic heteroaryl group of pyrimidine, thiazopyridine, benzotriazole, or benzoxazole; wherein the optionally substituted bicyclic group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted pyrrolidine, The heterocycle of pyrrolidone, piperidine, or morpholine, optionally substituted phenyl, or optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocycle, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 R3 is -H, methyl or trifluoromethyl, R4 is -H or halogen, R8 and R are each -H, R5 is -H, halogen, methyl or trifluoromethyl, R6 is -H or halogen, and R7 is C1-C3 alkyl (preferably methyl).

[0343] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0344] R9 is -H, halogen, or trifluoromethyl (preferably, R9 is -H or trifluoromethyl), and R2 is optionally substituted with a compound selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindoline-1-one, indoline-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one, or 2,3-dihydro-[1,4]dioxacyclohexen[2,3-b]pyridine (preferably 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene). A bicyclic compound of indole, isoindoline-1-one, indoline-2-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted with a compound selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, benzoxazole, benzothiazole, pyrrolopyrazine, or quinazoline (preferably indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole). The bicyclic heteroaryl group of pyrrolopyrimidine, thiazopyridine, benzotriazole, or benzoxazole; wherein the optionally substituted bicyclic group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted from pyrrolopyrimidine, thiazopyridine, benzotriazole, or benzoxazole; The C1-C6 alkyl group is a heterocyclic compound of an alkyl group, pyrrolidone, piperidine, or morpholine, optionally substituted with a phenyl group, or optionally substituted with a heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy group; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR 10 R 10 R3 is -H or -CN, R4, R8 and R are each -H, R5 is -H, halogen, methyl or trifluoromethyl, R6 is -H or halogen, and R7 is C1-C3 alkyl (preferably methyl).

[0345] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0346] R9 is -H, a halogen, or a trifluoromethyl group (preferably, R9 is -H or a trifluoromethyl group), and R2 is a bicyclic ring optionally substituted from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted from a bicyclic heteroaryl group selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, or phthalazine; wherein the optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, a halogen, or a C1-C6 alkyl group. The C1-C6 alkyl group, C1-C6 alkoxy group, C1-C6 haloalkoxy group, optionally substituted C1-C6 alkyl group, optionally substituted C3-C5 cycloalkyl group, optionally substituted heterocyclic group selected from pyrrolidine, pyrrolidone, piperidine or morpholine, optionally substituted phenyl group, or optionally substituted heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH or C1-C3 alkoxy group; wherein the optionally substituted C3-C5 cycloalkyl group, phenyl group, heterocyclic group or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl group, C1-C3 haloalkyl group, C1-C3 alkoxy group, C1-C3 haloalkoxy group, -NR group. 10 R 10 R3 is -H or -CN, R4, R8 and R are each -H, R5 is -H, halogen, methyl or trifluoromethyl, R6 is -H or halogen, and R7 is C1-C3 alkyl (preferably methyl).

[0347] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0348] R9 is -H, a halogen, or a trifluoromethyl group (preferably, R9 is -H or a halogen), and R2 is optionally substituted with a group selected from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindolin-1-one, indololin-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one, or 2,3-dihydro-[1,4]dioxane-[2,3-b]pyridine (preferably 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane). The bicyclic ring of isoindoline-1-one, indoline-2-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted with a ring selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, benzoxazole, benzothiazole, pyrrolopyridine, or quinazoline (preferably indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole). A bicyclic heteroaryl group of pyrrolopyrimidine, thiazopyridine, benzotriazole, or benzoxazole; wherein the optionally substituted bicyclic group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; wherein the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C5 cycloalkyl, optionally substituted pyrroloalkyl. The C1-C6 alkyl group is a heterocyclic compound of pyrrolidone, piperidine, or morpholine, optionally substituted with a phenyl group, or optionally substituted with a heteroaryl group selected from pyrazole, isoxazole, isothiazole, imidazole, oxazole, or thiazole; wherein the optionally substituted C1-C6 alkyl group is optionally substituted with -CN, -OH, or C1-C3 alkoxy; wherein the optionally substituted C3-C5 cycloalkyl, phenyl, heterocyclic, or heteroaryl group is each optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, -NR. 10 R 10 R3 is -H or -CN, R4, R8 and R are each -H, R5 is -H, halogen, methyl or trifluoromethyl, R6 is -H or halogen, and R7 is C1-C3 alkyl (preferably methyl).

[0349] In another compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof, R1 is a group of the following formula:

[0350] Wherein R9 is -H, halogen, methyl, trifluoromethyl, or cyclopropyl, and R2 is optionally substituted from 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindoline-1-one, indoline-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one, or 2,3-dihydro-[1,4]dioxane-[2,3-b]pyridine (preferably 1,3-benzodioxane, 2,3-dihydro-1,4-benzodioxane, isoindoline-2-one, etc.). A bicyclic ring of 1-one, indoline-2-one, or benzo[d]oxazol-2(3H)-one, or optionally substituted with a ring selected from indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolopyridine, benzimidazole, pyrrolopyrimidine, thiazopyridine, benzotriazole, benzoxazole, benzothiazole, pyrrolopyrazine, or quinazoline (preferably indole, indazole, pyrrolopyridine, furanopyridine, pyrazolopyridine, imidazopyridine, pyrazolopyrimidine, imidazopyridazine, phthalazine, triazolo...

Claims

1. The following compound: Or its pharmaceutically acceptable salt, wherein: R is -H; R1 is a group in the following formula: ; ; ; ; ;or ; R2 is a bicyclic compound optionally substituted with one selected from 1,3-benzodioxacyclopentene, 2,3-dihydro-1,4-benzodioxacyclohexene, isoindoline-1-one, indoline-2-one, benzo[d]oxazol-2(3H)-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one, or 2,3-dihydro-[1,4]dioxacyclohexeno[2,3-b]pyridine, or optionally substituted with one to ten cyclic atoms containing one, two, three, four, or five independent cyclic heteroatoms selected from N, O, or S. Cycloheteroaryl; wherein the optionally substituted bicyclic ring is optionally substituted with 1 to 3 substituents, each substituent being independently selected from halogens and C1-C6 alkyl groups; the optionally substituted bicyclic heteroaryl group is optionally substituted with 1 to 3 substituents, each substituent being independently selected from -CN, halogens, C1-C6 haloalkyl groups, C1-C6 alkoxy groups, C1-C6 alkyl groups optionally substituted with -OH, oxadiazine, or phenyl groups, or heteroaryl groups selected from pyridine, pyrimidine, pyridazine, pyrazine, pyrazole, isoxazole, isothiazine, imidazole, or oxazole; R3 is -H, -CN, C1-C6 alkyl, or C1-C6 haloalkyl; Each of R4, R5 and R6 is independently -H, halogen, C1-C6 alkyl or C1-C6 haloalkyl; R7 is a C1-C6 alkyl group; R8 is -H; and Each R9 is independently -H, halogen, C1-C6 alkyl, or C1-C6 haloalkyl.

2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, said compound having the following formula: 。 3. The compound of claim 1 or claim 2, or a pharmaceutically acceptable salt thereof, wherein R1 is a group of the following formula: ; ; ; ;or .

4. The compound of claim 1 or claim 2, or a pharmaceutically acceptable salt thereof, wherein R1 is a group of the following formula: ; ; ; ;or .

5. The compound of claim 1 or claim 2 or a pharmaceutically acceptable salt thereof, wherein each R9 is independently -H, halogen, C1-C3 alkyl or C1-C3 haloalkyl.

6. The compound of claim 1 or claim 2, or a pharmaceutically acceptable salt thereof, wherein R1 is a group of the following formula: ; ; ; ; ; ;or .

7. The compound of claim 1 or claim 2, or a pharmaceutically acceptable salt thereof, wherein R2 is a group of the following formula: ;or .

8. The compound of claim 1 or claim 2, or a pharmaceutically acceptable salt thereof, wherein R2 is a group of the following formula: ;or .

9. The compound of claim 1 or claim 2 or a pharmaceutically acceptable salt thereof, wherein R3 is -H, -CN, C1-C3 alkyl or C1-C3 haloalkyl.

10. The compound of claim 1 or claim 2 or a pharmaceutically acceptable salt thereof, wherein R3 is -H or methyl.

11. The compound of claim 1 or claim 2, or a pharmaceutically acceptable salt thereof, wherein R4 is -H.

12. The compound of claim 1 or claim 2 or a pharmaceutically acceptable salt thereof, wherein R5 is -H, halogen, C1-C3 alkyl or C1-C3 haloalkyl.

13. The compound of claim 1 or claim 2 or a pharmaceutically acceptable salt thereof, wherein R6 is -H or a halogen.

14. The compound of claim 1 or claim 2, or a pharmaceutically acceptable salt thereof, wherein R7 is methyl.

15. A compound selected from: ;and ; Or its pharmaceutically acceptable salt.

16. Compounds selected from: and ; Or its pharmaceutically acceptable salt.

17. Compounds selected from: and ; Or its pharmaceutically acceptable salt.

18. Compounds selected from: ;and ; Or its pharmaceutically acceptable salt.

19. Compounds selected from: and ; Or its pharmaceutically acceptable salt.

20. A pharmaceutical composition comprising a compound according to any one of claims 1-19 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

21. Use of the compound of any one of claims 1-19 or a pharmaceutically acceptable salt thereof or the pharmaceutical composition of claim 20 in the preparation of a medicament for regulating PI3K.

22. Use of the compound of any one of claims 1-19 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment of breast cancer.

Citation Information

Patent Citations

  • Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3k) for the treatment of diseases associated with p13k modulation

    WO2021202964A1